Cellular labeling and quantification for nuclear magnetic resonance techniques

专利摘要:

公开号:AU2007238586A1
申请号:U2007238586
申请日:2007-04-16
公开日:2007-10-25
发明作者:Eric T. Ahrens；Mangala Srinivas
申请人:Carnegie Mellon University；
IPC主号:C12N5-00

专利说明:
WO 2007/120911 PCT/US2007/009391 1 CELLULAR LABELING AND QUANTIFICATION FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES RELATED APPLICATIONS 5 This application claims the benefit of U.S. Provisional Patent Application Serial No. 60/792,003, filed on April 14, 2006, the entire disclosure of which is incorporated herein by this reference. STATEMENT REGARDING FEDERALLY-SPONSORED RESEARCH OR 10 DEVELOPMENT The invention described herein was supported, in whole or in part, by Federal Grant Nos RO1-EB003453, ROI-EB004155, P01-HD047675, P50 ES012359, and P41EB-001977. The U.S. Government has certain rights in the invention. 15 BACKGROUND Many biological processes are carried out by populations of cells. For example, cells of the immune system are recruited from the bloodstream to areas of inflammation or infection, resulting in an accumulation of immune cells at the 20 affected site. A marked infiltration of immune cells often occurs in tissues affected by autoimmune diseases, cancers and infections. Likewise, transplant rejection is mediated by host immune cells that enter and destroy the transplanted tissue. There is also growing evidence that stem cells originating in the bone marrow migrate through the bloodstream and assist in the regeneration of damaged tissues. 25 Furthermore, the most immediately promising area of biologic therapy involves the emerging field of cellular therapy. Cellular therapy is broadly defined as the treatment of human disease by the administration of therapeutic cells that have been selected, multiplied, and pharmacologically treated outside the body, or ex vivo. These cells may be derived from the patient (autologous cells), from another WO 2007/120911 PCT/US2007/009391 2 human (allogenic cells), from other organisms (xenogenic cells), or from immortalized cell lines. Cells represent the ultimate therapeutic system because of their ability to carry out complex functions and their responsiveness to changes in the surrounding 5 tissue or host organism. In the simplest mode of cellular therapy, cells can be isolated, grown in quantity ex vivo, and implanted in patients to produce and secrete soluble factors that directly address the mechanism of disease. Cells can also accomplish tasks as complex as reconstitution of tissues, organs, or immune responses based on their ability to home to specific sites within the body, to exit 10 from circulation, and to integrate into specific tissue or differentiate into new tissue. Other cellular therapeutics can be programmed for tumor killing or treating metastases (e.g., immunotherapeutics). Although dynamic cell populations play a key role in significant diseases, present technologies for monitoring the location and movement of cells in vivo are 15 quite limited. Typically, cell movements are monitored only in "snap shots" obtained by histological analysis of tissue biopsies. However, the process of sampling a tissue often alters the behavior of cells, and only a limited number of biopsies can be obtained from a particular tissue or organ. Some progress has been made studying cell movements via in vitro assays and isolated tissues ex-vivo. 20 Existing instruments for non-invasive analysis of living organisms are, at present, ill-suited for tracking living cells. Light-based imaging technologies, such as bioluminescence (e.g. luciferases) technologies, are often ineffective at visualizing deep structures because most mammalian tissues are optically opaque. Positron emission tomography (PET) techniques using radioactively-labeled probes are 25 highly sensitive. However, PET instrumentation is often limited to a resolution of several millimeters and is unable to resolve fine details of tissues and organs. Furthermore, labeled cells cannot be detected for time periods that extend beyond a typical PET radioisotope half-life, and generally PET is not useful for longitudinal studies. In order to gain a fundamental understanding of cellular processes, new 30 ways to visualize and quantify the population dynamics of specific cell types in vivo must be developed.
WO 2007/120911 PCT/US2007/009391 3 Magnetic resonance imaging (MRI) is a widely used clinical diagnostic tool because it is non-invasive, allows views into optically opaque subjects, and provides contrast among soft tissues at reasonably high spatial resolution. Conventional MRI focuses almost exclusively on visualizing anatomy and has no specificity for any 5 particular cell type. The 'probe' used by conventional MRI is the ubiquitous proton ('H) in mobile water molecules. New classes of exogenous MRI probes or reagents are needed to facilitate cell-specific imaging in living subjects. SUMMARY 10 In certain aspects, the disclosure provides novel methods and reagents for labeling cells ex vivo with an imaging reagent, such as fluorocarbon imaging reagent that can be detected by a nuclear magnetic resonance technique. In certain aspects, the disclosure provides methods and software for quantifying the numbers of labeled cells at particular locations in vivo. Cells may be labeled with a label including a 15 fluorocarbon, for example a perfluoropolyether (PFPE), and since biological'tissues have negligible endogenous fluorine content, in vivo '9F MRI can provide an effective means of detecting labeled cells. In some embodiments these images are then superimposed on a conventional 'H MRI to determine anatomical localization. Labeled cells may be administered to a subject and subsequently detected by 20 nuclear magnetic resonance techniques. Examples of nuclear magnetic resonance techniques include magnetic resonance imaging (MRI) and localized magnetic resonance spectroscopy (MRS). Because nuclear magnetic resonance techniques are generally performed as non-invasive procedures, the labeled cells may be detected at one or more time points in a living subject. Labeled cells may also be detected in a 25 cell culture or in essentially any other milieu on which a nuclear magnetic resonance technique can be performed, such as tissue explants, organs and tissues removed from a subject (possibly prior to transplant into a transplant recipient), artificially generated tissues and various matrices and structures seeded with cells. In certain aspects, the disclosure provides methods for labeling a cell. Such 30 methods may include contacting the cultured cells ex vivo with a fluorocarbon imaging reagent under conditions such that the fluorocarbon imaging reagent WO 2007/120911 PCT/US2007/009391 4 becomes associated with the cell. Perfluoropolyethers (PFPEs) are examples of suitable fluorocarbon imaging reagents. Perfluoropolyethers may be linear or cyclic (e.g., perfluoro-crown ethers). An imaging reagent may be formulated as an emulsion, often including a surfactant. An example would be an emulsion 5 comprising PFPE (Exfluor, Round Rock, TX) and Pluronic L-35 or F68 (Sigma Aldrich, St. Louis, MO). Optionally, the cell may be contacted with the fluorocarbon imaging reagent in the presence of a reagent that enhances uptake of the fluorocarbon imaging reagent. Various cationic molecules, such as cationic lipids or protamine sulfate, are examples of a suitable uptake enhancing reagent; other such 10 reagents are described herein and are, in view of this specification, known in the art. In certain embodiments, the composition of the surfactant may be designed to impart a cationic surface to the emulsion particle that enhances cellular uptake of the emulsion without the need of an enhancing reagent. In certain embodiments, the cells are labeled with perfluorocarbon emulsion particles by electroporation. 15 While a fluorocarbon imaging reagent may be internalized by a cell, it may also associate with the extracellular surface of a cell. Association with an extracellular surface may be increased by conjugating the imaging reagent to a cellular targeting moiety. A cellular targeting moiety may be essentially any molecular entity that binds to the desired cells, such as an antibody that binds to an 20 epitope that is exposed to the extracellular milieu. Uptake of an imaging reagent into a cell may be increased by conjugating the imaging reagent to an internalization moiety. An internalization moiety is any molecular entity that stimulates or promotes entry of the imaging reagent into the cell. Examples include internalizing peptides and moieties that bind to receptors or other cell surface proteins that are 25 internalized by, for example, receptor mediated endocytosis. The cell may be essentially any cell, including prokaryotic and eukaryotic cells. In preferred embodiments, the cell is a mammalian cell. In certain embodiments the cell is a cell of the immune system, such as a dendritic cell or T cell. A cell may also be a stem cell or a cell that has been prepared for administration to a subject as part of a 30 cellular therapy or a transplant, such as a peripheral blood stem cell transplant or bone marrow transplant. Other cell types can be labeled and imaged, for example an WO 2007/120911 PCT/US2007/009391 5 embryonic stem cell, a pancreatic islet, a hepatocyte, etc., perhaps in conjunction with a therapy. In certain aspects, the disclosure provides methods of labeling cells with fluorocarbon imaging reagents. Preferred fluorocarbon imaging reagents have one 5 or more of the following properties: reduced cytotoxicity; a ' 9 F NMR spectrum that is simple, ideally having mostly a single, narrow resonance to minimize chemical shift artifacts; a large number of NMR-equivalent fluorine atoms per molecule; and suitability for formulation to permit efficient labeling of many cell types. Preferred fluorocarbon imaging reagents include, linear or cyclic perfluoroethers (e.g., 10 perfluoro-crown ethers). Preferred perfluoro-crown ethers include perfluoro-1 5 crown-5, perfluoro-18-crown-6 and perfluoro-12-crown-4. In certain embodiments, the fluorocarbon imaging reagent is a perfluorinated polyether having an average formula: XO(Y-O)nZ 15 wherein Y is selected from the group comprising: F F F F F I | I | I C---C , -C--C- and I I | I I F F F F F F F F F I | I I C---C--C F F- F F wherein n is an integer from 8 to 20; wherein X and Z are the same and are selected from the group comprising: perfluoroalkyls, perfluoroethers, fluoroalkyls terminated with fluoroacy1, carboxyl, amide or ester, methylols, acid chlorides, amides, 20 amidines, acrylates and esters. In a particularly preferred embodiment, n is 10-12, most preferably 1 1. In a further embodiment, X and/or Z are polyethers that are terminated with a group (e.g. a carboxyl group) that facilitates the addition of further moieties. Optionally, the imaging reagent comprises an additional functional moiety. The additional functional moiety may be a detection moiety that facilitates WO 2007/120911 PCT/US2007/009391 6 detection of the reagent by a technique other than a nuclear magnetic resonance technique. Examples of detection moieties include fluorescent detection moieties and PET detection moieties. Accordingly, the disclosure provides linear fluorocarbons derivatized at one or more polymer ends with at least one functional 5 moiety, wherein at least one functional moiety is selected from the group comprising: a detection moiety, a hydrophilic moiety, a targeting moiety and a cellular uptake moiety. The incorporation of a detection moiety creates a dual (or higher order) labeling moiety that facilitates detection by more than one technique (e.g., PET and MRI or fluorescence microscopy and MRS). Optionally, an imaging 10 reagent may be formulated as an emulsion. Preferred emulsions will be stable at body temperature (37*C for humans) and at a storage temperature, such as 4*C or room temperature (20-25'C). Preferably an emulsion is designed to facilitate uptake of the imaging agent by the subject cells. An emulsion may have an average particle (or droplet) size of between 10 and 500 nm in diameter (meaning that the emulsion 15 may contain particles smaller than 10 nm in diameter or larger than 500 nm in diameter, but having an arithmetical mean particle diameter falling between 10 and 500 nm, as calculated by methods known in the art). In one embodiment the average particle diameter of the emulsion will be between 30 and 300 nm or between 30 and 200 nm less than 20, 10, or 5 nm. Preferably, the average particle diameter of the 20 emulsion will be 90 - 120 nm or 100 - 110 nrm +/- less than 80, 40, 20, 10, or 5 nm. In certain aspects, the disclosure provides methods for detecting a cell in a subject. A method may comprise: administering to the subject a cell that is labeled with a fluorocarbon imaging reagent and examining at least a portion of the subject by a nuclear magnetic resonance technique. Such analysis may include MRI or 25 MRS, which may include collecting data for and generating an image of 1 9 F distribution. Imaging may also include collecting data for and generating a conventional anatomical 'H image. In a preferred embodiment, 1 9 F and 'H images are generated and compared, optionally by superposition or overlay. Optionally, labeled cells may be detected using 19F MRS. In a preferred embodiment a 30 conventional anatomical 'H image is used as a template to guide the positions of one or more localized voxels for 1 9 F MRS. NMR data is understood to include both raw and processed data.
WO 2007/120911 PCT/US2007/009391 7 In certain aspects, the disclosure provides a method for quantifying cell number in vivo. A method may comprise administering to a subject, cells that are labeled with a fluorocarbon imaging reagent; and examining at least a portion of the subject by a nuclear magnetic resonance technique, thereby detecting labeled cells in 5 the subject; and quantifying the number of labeled cells in a region of interest (ROI). In certain embodiments the disclosure provides a method for quantifying labeled cells in a recipient of a transplant that includes labeled cells. Calibrating the mean "cellular dose" of labeling agent of a particular cell population may be a pre-requisite for in vivo quantitative determinations. The in vivo 10 equivalent of the cellular dose will be referred to as the number of 1 9 F molecules (F's) per cell or cell quantity, but is understood to be any measure of the amount of label per cell in vivo. In certain embodiments the mean number of 1 9 F molecules (F's) per cell or cell quantity of a labeled cell population is first measured (i.e., calibrated) in vitro prior to administration of cells to the subject or transplantation. 15 In certain embodiments the mean number of 1 9 F molecules (F's) per cell or cell quantity of a labeled cell population is measured (i.e., calibrated) contemporaneously with examination of labeled cells. In certain embodiments the mean number of 1 9 F molecules (F's) per cell or cell quantity of a labeled cell population is calibrated after the labeled cells have been examined. In certain 20 embodiments the mean number of ' 9 F molecules (F's) per cell or cellular dose of a labeled cell population is calibrated in a test population of cells of a particular type, not necessarily destined for a patient, but used to calibrate cellular dose of labeling agent as a consequence of a particular labeling protocol or set of conditions; the value of cellular dose is then used to for future labeling and in vivo imaging 25 experiments in the same population type of cells with the same labeling protocol. In certain embodiments the cellular dose or cell quantity of labeling agent is assayed using a variety of quantitative techniques, for example using the integrated area of a 1 9 F NMR spectrum of a cell pellet of a known number of labeled cells. Besides 1 9 F NMR, many other quantitative methods can be used to assay the cell quantity or 30 cellular dose of the labeling reagent, as described herein. In certain embodiments, the cell quantity or cellular dose can be represented or deduced from prior data. In certain embodiments, the cellular dose or cell quantity may not be directly counted WO 2007/120911 PCT/US2007/009391 8 in F' 9 molecules, but the units of the cellular dose of labeling reagent will be representative of this and will be understood to be equivalent. In certain embodiments, quantifying includes using a calibrated 1 9 F signal in the ROL A calibrated 1 9 F signal is a signal that, by virtue of any of the various 5 calibration techniques described herein, or other techniques that will be apparent from this description, is such that one can deduce a relationship between the signal and the representative number of ' 9 F molecules or cell quantity. As an example, calibration may be achieved by placing a vial of known quantity of 1 9 F molecules in the MRI detection field during imaging of the ROI. This permits one to calculate 10 the relationship between the signal strength within the ROI and the number of 19F molecules. In certain embodiments, the disclosure provides a method of quantifying the numbers of labeled cells in vivo within an ROI. For example, following cell administration, and in vivo 1F MRI/MRS, one can compare the total (e.g. 15 integrated) 1 9 F signal intensity in an ROI to a calibrated 1 9 F reference. The ' 9 F reference may be, for example, a vessel containing a solution with a known concentration of ' 9 F nuclei. The vessel would be placed preferably externally or alongside, or optionally inside, the imaged subject or patient prior to data acquisition. In preferred embodiments, the reference is imaged along with the 20 subject in the same image field of view. Optionally, the reference can be imaged in a separate scan, or no external reference can be used. By computationally manipulating or combining a key set of parameters from the 1 9 F MRI/MRS data set, one can calculate the number of labeled cells present in an ROI as described herein. For example, a key set of parameters may include: (i) 25 the cellular dose of labeling agent (i.e., Fc) measured in vitro; (ii) in vivo ' 9 F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane voxel area (i.e., area of the image pixel); (v) optionally, the MRI/MRS data set from the 1 9 F reference standard; (vi) optionally, the measured Johnson noise of the 1F MRI/MRS data in 30 the subject material; (vii) optionally, the measured signal-to-noise ratio (SNR) of one or more voxels of the 1 9 F MRI/MRS data set in the subject material; (viii) optionally, the measured SNR of one or more voxels of the 19F MRI/MRS data set WO 2007/120911 PCT/US2007/009391 9 from the reference standard; (ix) optionally, the ' 9 F NMR relaxation times (TI, T2, and T2*) of the subject material; (x) optionally, the 1 9 F NMR relaxation times (TI, T2, and T2*) of the reference standard (for example, see Magnetic Resonance Imaging, Third Edition, chapter 4, editors D.D. Stark and W.G. Bradley, Mosby, 5 Inc., St. Louis MO 1999). Those skilled in the art can derive other parameters, combinations of the above set, or derivations thereof, particularly from the ' 9 F MRI/MRS dataset, that can be used to quantify the number of labeled cells in situ. In certain embodiments the above set of key parameters can be used to derive quantitative or statistical measures of the accuracy or confidence of the measured 10 number of labeled cells. There are many ways to combine the key parameters (i-x, above), any subsets of these, or any of their combinations or approximations, to estimate the effective number of labeled cells seen by 1 9 F MRI in the subject material, denoted by N,. For example, one can use an equation of the form N = [ FR IV 1 c R F,: C 15 where: Ne = total number of labeled cells in the ROI; [FR] = concentration of ' 9 F in the calibrated 1 9 F reference solution (or gel); v = voxel volume; IR = mean intensity of the calibrated ' 9 F reference taken with the MRI/MRS scan, averaged over one or more voxels; F, = average 19F cellular dose of the labeling agent measured in vitro; NROI = number of voxels in the ROI containing labeled cells; Ic = image intensity 20 of the ith voxel in the ROI containing labeled cells; i = unitless index for voxels in the ROI containing labeled cells. In certain aspects, the disclosure provides a calculating system for the quantification of 1 9 F labeled cells and optionally, a statistical measure of the uncertainty in the measured cell number. In certain embodiments the disclosure 25 provides a computer; a computer readable medium, operatively coupled to the computer, and computer readable medium program codes that can quantify the number of ' 9 F labeled cells in a ROI in vivo. In certain embodiments the system calculates the number of labeled cells by ratios of the intensity of 1 9 F signal and the volume of labeled cells in a ROI compared to a reference. In certain embodiments 30 the system calculates the number of labeled cells according to a formula, an example WO 2007/120911 PCT/US2007/009391 10 of which is stated above. In certain embodiments the quantification comprises relating a calibrated NMR signal to a cellular dose. In certain aspects, the disclosure provides a computer readable medium having computer readable program codes embodied therein for performing in vivo 5 quantification of 1 9 F labeled cells and optionally, a statistical measure of the uncertainty in the measured cell number. In certain aspects the computer readable medium program codes calculate the number of 1 9 F labeled cells in a ROI detected by a magnetic resonance technique. In certain embodiments the system calculates the number of labeled cells by ratios of the intensity of 1 9 F signal and the volume of 10 labeled cells in a ROI compared to a reference. In certain embodiments the system calculates the number of labeled cells according to a formula. In certain embodiments the same computer can be used to calculate a statistical confidence coefficient accompanying the cell number calculation. In certain embodiments the quantification comprises relating a calibrated NMR signal to a cellular dose. 15 As will be apparent from this disclosure, methods described herein will be useful in a variety of clinical procedures. For example, the disclosure provides methods for detecting donor cells in a recipient, such as a transplant recipient or a recipient of other types of cell-based therapy. Such a method may comprise administering cells for transplant to a transplant recipient, at least a portion of which 20 cells for transplant are labeled with a fluorocarbon imaging reagent; and examining at least a portion of the subject by a nuclear magnetic resonance technique, thereby detecting the labeled cells. Detection of the labeled cells may be done once or repeatedly and may be performed so as to provide information about the location and trafficking of labeled cells in the transplant recipient. Examples of cell 25 recipients include recipients of bone marrow transplants (or cellular fractions containing hematopoietic stem cells, commonly but not exclusively derived from bone marrow, peripheral blood or cord blood) and other cell or organ transplant recipients. Organ transplant recipients include recipients of donor organs such as liver, heart, lung, kidney, pancreatic tissue, neural tissue or other transplants. 30 Recipients also include recipients of donor cells, which may be derived directly from a donor (in the case of autologous cells, the "donor" is the same individual as the recipient) or subjected to limited or extensive culturing prior to use. Donor cells WO 2007/120911 PCT/US2007/009391 11 may be derived from essentially any tissue that serves as a source of useful cells, and may include stem cells (including precursor cells), such as hematopoietic stem cells, hemangioblasts, hepatic stem cells, neural stem cells, muscle stem cells (e.g. satellite cells), cardiomyocyte precursor cells, pancreatic stem cells, vascular endothelial 5 precursor cells, mesenchymal stem cells, bone or cartilage precursor cells, or may include mature cells, such as dendritic cells, immune cells (e.g., T cells, B cells), chondrocytes, osteoblasts, and the like. Cells for administration may be autologous, heterologous or even derived from another organism, such as a pig. Other aspects of the present invention will be apparent from the disclosure below. 10 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. Schematic diagram of pathway for cell labeling, imaging, and quantification. The dashed connections denote optional steps. 15 Figure 2. Illustration of cells being labeled ex vivo, transferred into a host, and imaged using ' 9 F and 'H, and visualized via a composite 1 9 F/'H image. Figures 3A-3D. T cells are efficiently labeled with PFPE nanoparticles ex vivo. (a) Shows a 1F NMR spectrum of pelleted, labeled (Ix106 ) T cells. The PFPE has two 20 peaks, one at -92 ppm and the other at -79 ppm. A capillary containing trifluoroacetic acid (TFA) was used as a reference alongside the cell pellet and shows a peak at -76 ppm. The ' 9 F NMR was measured at 470 MHz. (b) Confocal fluorescence micrographs of labeled, activated T cells. The PFPE nanoparticles were treated with Dil (pink) before cell labeling. Cell nuclei are TOTO3 stained (blue), 25 which also weakly stains the cytoplasm. Nanoparticles are visible both on the cell surface and intracellularly. The scale bar represents 8 pm. (c) Molecular structure of the PFPE, a dimethyl ester derivative of PEG 600, with approximately 40 F's per molecule. This molecule can be emulsified, for example, using Pluronic L35. (d) Emulsion particle size as seen by dynamic light scattering (left panel) and electron 30 microscopy (EM) (right panel). The dynamic light scattering measured the size distribution of the nanoparticles in PBS. The plot shows the mean number of WO 2007/120911 PCT/US2007/009391 12 nanoparticles (%) versus the mean particle diameter (nm). The nanoparticles have an average diameter of 103 ± 4 nm. Figures 4A-4B. In vitro cell labeling with fluorocarbons (i.e., PFPE) emulsions 5 using various transfection agents. The agents shown are protamine sulfate (Sigma, Inc.), Lipofectamine (Invitrogen, Inc.),. DOTAP (Roche, Inc.), and FuGene (Roche, Inc.). Examples are given for typical cell types, including dendritic cells (DCs) (panel a) and T-cells (panels b). In panels a-b, different cationic transfection reagents were used to significantly boost uptake in culture of the PFPE particles and 10 reduce labeling incubation time to of order of 1-3 hours. The 19 F content was assayed using integrated 1 9 F NMR spectra of labeled cell pellets, where values were normalized to cell number and a TFA reference located next to the cell pellet. Figures 5A-5B. In vitro cell labeling with perfluorocarbon (i.e., PFPE) emulsion 15 particles using electroporation. DCs were electroporated in culture media. Panel a shows a typical 1F NMR spectrum of a pellet of labeled cells. Panel b shows the 1 9 F content as a function of electroporation voltage, at fixed PFPE concentration in the medium. The intracellular 19 F content was assayed using 1 9 F NMR spectroscopy of labeled cell pellets, where values are normalized to cell number and a TFA reference 20 located next to the cell pellet. Figure 6. MTT toxicity assay of PFPE labeled primary T-cells in vitro. Minimal toxicity is observed due to PFPE labeling. Data is taken from aliquots of cells taken at 2 hrs and 4 hrs after labeling. In this example a transfection agent (FuGene) was 25 used to boost uptake. Data was normalized to the untreated control, multiplied by 100, and the experiment was averaged over n = 9 trials. Figures 7A-7C. FACS results in PFPE labeled T cells. Panels (a) and (b) are CD62L+ and CD4+ expression levels, respectively, at 4 and 24 hours post-labeling 30 using the transfection agent method. Panel (c) shows CD4+ and CD62L+ expression at 4 hours post-labeling via electroporation.
WO 2007/120911 PCT/US2007/009391 13 Figure 8. Fluorescence micrographs of histological sections of pancreatic tissue from a NOD SCID mouse receiving PFPE labeled T cells. Mice received 4x10 6 labeled BDC2.5 T cells 48 hours prior. The fixed section staining is as follows: insulin is stained green, nuclei white, actin blue, and T cells red. The images show 5 early insulitis, with T cells infiltrating into the islets or around blood vessels, suggesting that PFPE labeling does not impair T cell trafficking. Figures 9A-9D. In vivo MRI showing transferred T cells homing to the pancreas. Panels (a)-(c) are composite 19 F/'H images through the mouse torso, where the 19F is 10 rendered in pseudo-color and the 'H is in grayscale. Only slices containing 19F signal are shown. (a) Image of PFPE labeled, in vitro activated diabetogenic T cells (5x 106) transferred i.p. into an NOD SCID mouse 48 hours prior. The image shows specific T cells (pseudo-color) homing to the pancreas (P). The ' 9 F reference capillary (R) is placed next to the mouse. The lungs, spleen (S) and liver (L) are 15 labeled. Panel (b) shows a negative control image of an NOD SCID mouse that received cell-free PFPE nanoparticles in PBS at an equivalent ' 9 F dose of 1x107 labeled T cells. We detected the PFPE (pseudo-color) only near the gut (G). Panel (c) shows a negative control image of a NOD SCID mouse that received activated, labeled MHC-mismatched T cells. We did not detect a signal in or around the 20 pancreas; liver or spleen, but cells (pseudo-color) can be seen at a site near the kidney (K). Panel (d) shows results of the in vivo quantification of the apparent T cells homing to the pancreas for the cohort of NOD SCID mice. The values represent the percentage of cells detected in the pancreas compared to the total number of i.p. transferred cells, ranging from 2-6x 106 cells. See Methods for 25 explanation of error bars. Figures 10A-10B. 1 9 F NMR spectra of excised pancreas (a) and spleen (b) from an NOD SCID mouse inoculated with labeled T cells. ' 9 F NMR on whole, fixed organs was performed after in vivo MRI (Fig. 9a). The 1 9 F peak is detected in the pancreas 30 (a), but is absent in the spleen (b), consistent with the in vivo MRI findings (Fig. 9a). The TFA ' 9 F reference was located in a sealed capillary adjacent the organ. A larger number of averages (8-times) were used to acquire (b) compared to (a).
WO 2007/120911 PCT/US2007/009391 14 Figures 11A-11b. Phantom studies validating T cell quantification methods using 1 9 F MR images. Panel (a) shows a composite 19 F/'H image (left) and intensity rescaled 1 9 F image (right) through a phantom containing capillary tubes containing 5 different densities of labeled T cells suspended in agarose, where capillary A=12, B=6, C=3, D=1.5, and E=0.75 (x104) cells/voxel, and R is a calibrated 1 9 F reference capillary. The ' 9 F image (a, right) was rescaled to show the intermediate cell densities, i.e., capillaries B, C, D. Capillary E (7,500 cells/voxel) is not visible in this scaling, however, our quantitative analysis is able to detect and measure cells in 10 this sample. These data were acquired using similar imaging parameters as Fig. 9. A
CF
2 endgroup chemical shift artifact, or 'ghost', from the highly-concentrated R capillary is observed near capillary A. Panel (b) shows the actual versus MRI measured cell numbers in the phantom. The Pearson correlation coefficient is 0.98. The linear fit is a guide for the eye. The error bars for the ordinate are not shown and 15 are smaller than the data point symbol. Figure 12. Schematic showing the acute inflammation mouse model imaging experiment. Antigen-specific, MHC-matched T cells were in vitro activated prior to PFPE labeling and transfer. The host mice received s.c. ovalbumin/IFA in the 20 quadrucepts on the right side to initiate an inflammatory response, and a PBS injection in the left leg served as a control. The mice were then longitudinally imaged using 1F and 'H in the same imaging session at 2, 4, 7, 11 and 21 days after cell transfer. 25 Figure 13. Slices containing the inguinal lymph nodes at various time points after the injection of PFPE labeled T cells. The T cells are visible in the inguinal node (i, -4 day panels) only on the side where ovalbumin/IFA was administered. Some localization to the mesentery nodes is also observed (m, 4 day panel). Only slices with appreciable 1 9 F signal are shown. 30 WO 2007/120911 PCT/US2007/009391 15 Figure 14. Plot.of average number of T cells in the inguinal lymph node at day 2, 4, 7, 11 and 21 after cell transfer. These quantitative data were measured directly from the in vivo 1 9 F images. 5 Figures 15A-15B. In vivo optical imaging at day 4 after cell transfer. The Alexa PFPE label is visible through the skin at day 4 in shaved mice. (a) Fluorescence is concentrated in the mesenteric region, and in the draining inguinal lymph node. The box highlights the region over the draining inguinal. (b) To compare fluorescence in the inguinal nodes, without interference from the mesenteric region, the lymph 10 nodes were excised and imaged separately. The image is an overlay of the fluorescent image (false color) over a white light image. A difference in size as well as fluorescence is apparent in the inguinal lymph nodes, where the control lymph node is on the left. 15 Figure 16. A functional block diagram of a general purpose computer system 200 for performing the functions of the computer 104 according to an illustrative embodiment of the invention. DETAILED DESCRIPTION 20 1. Overview In certain aspects, the disclosure provides novel methods and reagents for labeling cells ex vivo with a nuclear magnetic resonance imaging reagent, such as a fluorocarbon imaging reagent and quantifying the labeled cells in vivo or ex vivo. Labeled cells may be detected by a 19F nuclear magnetic resonance technique (e.g., 25 MRI/MRS) and quantified according to methods described herein. ' 9 F nuclear magnetic resonance techniques are excellent imaging tools for biological systems because of the absence of endogenous background signals. Fluorine is present, if at all, at exceedingly low levels in living organisms, and generally not in a chemical form that is detectable by liquid-state nuclear magnetic resonance techniques. This 30 is quite distinct from conventional 'H MRI which, while providing visualization of fine anatomical detail, does not permit selective detection of particular cell WO 2007/120911 PCT/US2007/009391 16 populations. Certain methods disclosed herein permit whole or partial body screening to visualize the distribution of labeled cells in a living subject. The precise anatomical location of labeled cells detected by ' 9 F nuclear magnetic resonance may be determined by, for example, superimposition of a 'H MRI image 5 that provides anatomical detail. In preferred embodiments, the 'H image is acquired during the same imaging session as the 1 9 F image (without moving the subject) to ensure registration. Additionally, the nuclear magnetic resonance techniques disclosed herein may be applied effectively in ex vivo contexts, as in the case of tissue samples, excised organs and cell cultures. The imaging technology disclosed 10 herein may be applied to a large number of biological and medical problems. It certain aspects, a method of the invention may comprise labeling cells ex vivo with a 19F imaging reagent, administering the labeled cells to a subject, and detecting labeled cells in the subject. The cells to be labeled may be a crude cellular fraction or tissue sample, or the cells may be cultured and/or subjected to enrichment 15 prior to labeling. For example, particular cell types may be selected by fluorescence activated cell sorting (FACS) prior to labeling. Other sorting or selective enrichment methods are known in the art for the various different cell types that may be of interest. The types of cells that are labeled may also be controlled by the nature of the imaging reagent. For example, simple colloidal suspensions of 20 imaging reagent will tend to be taken up more quickly by cells with phagocytic activity. As another example, an imaging reagent may be formulated with or covalently bound to a targeting moiety that facilitates selective targeting of the imaging reagent to a particular population of cells. Imaging reagents are described further below. After labeling, cells may be immediately administered or the cells 25 may be stored, further cultured, purified, enriched, segregated or processed in any way that is not incompatible with the intended use of such cells. In certain aspects, labeled cells will be administered for a therapeutic purpose. Technology described herein may be used for monitoring the trafficking of cellular therapeutics ir vivo or in any other desired milieu, such as a tissue explant. 30 Bone marrow cell transplants have been widely used for many years in recipients of ablative therapies for cancers. Various purified cell populations have also been used in place of bone marrow, such as cell populations enriched for hematopoietic stem WO 2007/120911 PCT/US2007/009391 17 cells; for example cells may be harvested from umbilical cord blood or peripheral blood. After entering the bloodstream, the stem cells generally travel to the bone marrow, where they begin to produce new white blood cells, red blood cells, and platelets. This engrafiment usually occurs within about 2 to 4 weeks after 5 transplantation. Traditionally, engraftment is monitored by testing blood counts on a frequent basis, and complete recovery of immune function generally requires several months (for autologous transplant recipients) to years (for patients receiving allogeneic or syngeneic transplants). Cell sampling by bone marrow aspiration can provide further information on the function of the transplanted cells. These 10 monitoring techniques may be enhanced by ex vivo labeling of the cells to be transplanted (or some small fraction of such cells), thus permitting non-invasive monitoring of the location and movement of transplanted cells by nuclear magnetic resonance techniques. Non-myeloablative allogeneic transplantation (i.e. reduced intensity transplant) is a similar cell therapy that can be effective for treating several 15 types of cancer. Generally, this technique relies on a lower dose of radiation and/or chemotherapeutic and a limited graft-versus-host disease (the action of immune cells from the transplant against any residual host cancer cells) to provide sufficient anti cancer activity, as well as the hematopoietic potential of the graft cells to restore the patient's hematopoietic system. As with a traditional ablative graft, the techniques 20 of the present invention may be used to monitor the locations and movements of graft cells in a non-myeloablative allogeneic transplantation. Cellular therapeutics are also in development for use in the delivery of therapeutic proteins. In one embodiment, cells can be isolated, grown in quantity ex vivo and then implanted to produce and secrete soluble factors, which may be active 25 either locally (e.g. enzymes, cytokines, and neurotransmitters) or at a distance (e.g. hormones and growth regulators). Cells may also be administered to a patient in order to accomplish complex therapeutic purposes, such as reconstitution of tissues, organs, or immune responses based on their ability to home to specific sites within the body, exit from the circulation, and integrate into surrounding tissue or 30 differentiate to replace damaged tissue. Stem cell therapies have also been proposed for myriad diseases including neurological disorders, particularly those characterized by cell death (e.g., Parkinson's disease, stroke and brain injury caused by trauma), WO 2007/120911 PCT/US2007/009391 18 cardiovascular disorders (e.g., myocardial infarction), muscle regeneration (e.g., in patients suffering from cachexia or other wasting disorders), pancreatic regeneration in diabetes, liver regeneration, etc. In each instance, cells, or a sub-population thereof, may be labeled with an imaging reagent ex vivo prior to administration, thus 5 allowing the monitoring of these cells in vivo. In vivo monitoring by a nuclear magnetic resonance technique may be useful, for example, to evaluate the viability of the administered cells. A doctor may tailor a dosing schedule depending on the degree to which labeled cells are detected in a patient after administration. In vivo monitoring may also be useful in determining whether therapeutic cells have 10 localized to a desired location. In general, it will be possible to investigate correlations between the migration behavior of therapeutic cells in vivo, as well as the number and/or survivorship of therapeutic cells in vivo, and therapeutic outcomes. When such correlations have been established, the in vivo imaging of therapeutic cells may be used as a prognostic indicator that may be helpful in 15 selecting the appropriate dosage, administration modes and additional therapeutic interventions that will benefit the patient. Certain imaging advances of the invention will benefit a broad range of cellular therapeutic strategies because these imaging methodologies will be able to detect when, where and ifthe therapeutic cells have been delivered to the desired targets in vivo. Additionally, the detection of labeled 20 cells may be enhanced by quantification of labeled cells in a ROI, such as a particular organ or tissue. One example of an application of technology disclosed herein is in tracking dendritic cells (DCs). DCs are known to be the most efficient antigen presenting cells and have the capacity to stimulate naive T cells to initiate an immune response. 25 Because DCs are the most potent stimulators of immune response in the body, DCs represent a possible therapeutic approach to increasing the "visibility" of tumors to a patient's immune system. DCs are the focus of tumor vaccines in development. Varying methods are used to expose the dendritic cells to tumor antigens ex vivo, after which educated dendritic cells are reinfused to stimulate development of T-cell 30 mediated tumor killing. Data applying an embodiment of the present disclosure to the labeling and tracking of DCs and other cell types, presented in W02005072780, is incorporated by reference herein.
WO 2007/120911 PCT/US2007/009391 19 In addition to DCs, other cell types have demonstrated promise for immunotherapy in cancer and other diseases such as diabetes, although their progress has been hampered by many factors, including the inability to observe their movement following transplantation into animals and humans. Natural killer (NK) 5 cells, when harvested, treated ex vivo, and transplanted, have demonstrated the ability to kill metastatic tumor cells. Additional cell types treated ex vivo and transplanted to promote cancer immunity include lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes, and activated killer monocytes. Transplantation of T cells, which are white blood cells that attack pathogenic cells, 10 has demonstrated promise against a variety of cancers, including pancreatic cancer, in which clinical trials are beginning, and against multiple sclerosis and HIV infection. In certain aspects, labeled cells are administered to a subject for non therapeutic purposes. For example, cells may be labeled ex vivo, administered to a 15 subject and then detected, with the expectation that the labeled cells will behave similarly to like, unlabeled cells in vivo and may therefore be used to monitor the behavior of endogenous cell populations. Monitoring may be used for the purpose of tracking movements of cells, particularly in the case of cells that are known to be highly mobile, such as cells of the immune system, many types of stem cells and 20 blood born cells. Monitoring may also be used for the purpose of tracking viability or adherence of non-mobile cells at the site of implant. Cells of many tissues, such as muscle, liver, pancreas, kidney, brain or skin will tend to be relatively stationary, but disappearance of label may indicate a high death rate, low adherence, or other information. Modem cell culture and sorting techniques allow the selective pooling 25 and labeling of virtually any desired cell population, including various stem cell types, immune cell types, and other blood cell types. For example, cell surface markers can be used to sort mixed populations of cells to purify a population of interest. As described in the examples below, both T cells and dendritic cells may be labeled ex vivo and detected in vivo. 30 As an example, labeled immune cells may be used as detectable proxies for the movements of immune cells in a patient. Immune cells participate in and are markers for a host of inflammatory and autoimmune disorders, as well as cancer and WO 2007/120911 PCT/US2007/009391 20 atherosclerotic plaque formation. As a general methodology, any process involving the recruitment of immune cells may be detected in a patient by administering to the patient labeled immune cells. The accumulation of label in a particular area provides an indication of the degree of immune response occurring in that portion of 5 the body. Traditionally, these types of studies involve histological techniques that are incompatible with living subjects. Certain methods of the disclosure may facilitate the development of therapeutic strategies for the treatment of human diseases. The ability to track selected populations of immune cells non-invasively, and without the use of radioisotopes, can impact many areas of basic and clinical 10 immunology, such as multiple sclerosis, diabetes, monitoring organ transplant rejection, and cancer. For instance, tumors are often highly infiltrated by immune cells. Labeled cells may be imaged in a subject to reveal the location of a tumor, and in some instances may be useful as a non-invasive detection screen. Early detection of cancers has been a critical problem, as most early stage cancers are 15 readily treated by surgery without resort to debilitating chemotherapeutic agents. Likewise, the progress of other inflammatory diseases may be monitored by tracking the dynamics of immune cells in the patient. The effectiveness of immunosuppressant therapy may be assessed as well. In the instance of an organ transplant recipient, the recipient could receive a dose of labeled immune cells prior 20 to receiving the transplantation. In vivo monitoring of the accumulation of immune cells in the transplant could then be used as an early warning sign of rejection. In the case of transplants, the methods disclosed herein are particularly desirable because the alternative, biopsies, are well-known to increase the risk of organ rejection. 25 As an additional example, cells for use in a bone marrow cell transplant, or a peripheral blood stem cell transplant, may be labeled ex vivo as described herein, administered, and monitored in vivo by a nuclear magnetic resonance technique. Such monitoring may be used to evaluate the engraftment of donor cells in the recipient bone cavities, as well as survivorship and movement of labeled cells in the 30 recipient. A physician can use information relating to the trafficking of donor cells in a recipient as an early indication of the likely success or failure of the procedure. This type of early detection will allow physicians to tailor the post-transplant WO 2007/120911 PCT/US2007/009391 21 therapeutic regimen accordingly. Another cellular cancer therapeutic where the detection technology can be applied is the allogeneic non-myeloablative, or reduced intensity transplant. This procedure may be used with a donor lymphocyte infusion to boost graft-versus-tumor effect which destroys cancer cells. Here the entire 5 population, or a fraction, of transplanted cells could be labeled before infusion. A nuclear magnetic resonance technique could then be used determine where the cells traffic to in the body, which can be indicative of the efficacy of the procedure. As it is often desirable to limit the dose of allogeneic cells to minimize rejection, the cell's trafficking pattern may be used to calibrate dose. In the above cancer cell therapies it 10 may be desirable to selectively label one or more sub-population of the transplanted cells (e.g., CD34+ stem cells or T cells) that are believed to have therapeutic efficacy. As a further example, cells involved in formation of new tissue, such as in angiogenesis, can be labeled, administered to a subject, and detected to identify 15 hotspots of tissue formation. For example, smooth muscle cells and/or endothelial precursor cells may be labeled and introduced into the bloodstream. Such cells are expected to accumulate at sites of angiogenic activity. Angiogenic activity may be associated with physiological and pathological events such as menstrual cycling, early pregnancy, collateral vessel formation in response to arterial blockages, tumor 20 development and wound healing. Similarly, cells involved in wound healing, such as fibroblasts, may be labeled and administered systemically or to a site of suspected injury in order to monitor cellular behavior. For example, a medicament or delivery device containing labeled cardiomyocyte lineage cell aggregates or cells derived therefrom may be provided 25 for treatment of a human or animal body, including formulations for cardiac therapy. Cardiomyocyte lineage cells may be administered to a patient in a method for reconstituting or supplementing contractile and/or pacemaking activity in cardiac tissue (see US Patent Application No. 20060040389, 20050112104, 20050244384, which are incorporated in their entirety herein). . 30 In accordance with the present invention labeled cardiomyocyte lineage cells are used to regenerate or repair striated cardiac muscle that has been damaged through disease or degeneration. The labeled cardiomyocyte lineage cells integrate WO 2007/120911 PCT/US2007/009391 22 with the healthy tissue of the recipient to replace the function of the dead or damaged cells, thereby regenerating the cardiac muscle as a whole. Cardiac muscle does not normally have reparative potential. The labeled cardiomyocyte lineage cells are used, for example, in cardiac muscle regeneration for a number of principal 5 indications: (i) ischemic heart implantations, (ii) therapy for congestive heart failure patients, (iii) prevention of further disease for patients undergoing coronary artery bypass graft, (iv) conductive tissue regeneration, (v) vessel smooth muscle regeneration and (vi) valve regeneration. The administration of the cells can be directed to the heart, by a variety of 10 procedures. Localized administration is preferred. The mesenchymal stem cells can be from a spectrum of sources including, in order of preference: autologous, allogeneic, or xenogeneic. There are several embodiments to this aspect, including the following. The present invention allows monitoring of the progress of these cell in vivo. 15 The cardiomyocyte lineage cells may be cardiomyocyte precursor cells, or differentiated cardiomyocytes. Differentiated cardiomyocytes include one or more of primary cardiomyocytes, nodal (pacemaker) cardiomyocytes; conduction cardiomyocytes; and working (contractile) cardiomyocytes, which may be of atrial or ventricular type. In certain embodiments, cells come from a muscle sample (or 20 other sample) that contains muscle progenitor cells such as satellite cells (see US Patent Application No. 20050244384). In certain embodiments, cells are mesenchymal stem cells (MSCs) (see US Patent Application No. 20050112104). A "cardiomyocyte precursor" is defined as a cell that is capable (without dedifferentiation or reprogramming) of giving rise to progeny that include 25 cardiomyocytes. Such precursors may express markers typical of the lineage, including, without limitation, cardiac troponin I (cTnI), cardiac troponin T (cTnT), sarcomeric myosin heavy chain (MHC), GATA4, Nkx2.5, N-cadherin, .beta.I adrenoceptor (.beta.I-AR), ANF, the MEF-2 family of transcription factors, creatine kinase MB (CK-MB), myoglobin, or atrial natriuretic factor (ANF). 30 In certain instances, cells may prove to be so thoroughly associated with a biological site or structure of interest that the labeled cells may be administered for WO 2007/120911 PCT/US2007/009391 23 the sole purpose of aiding in the visualization of such a structure. As mentioned above, immune cells characteristically infiltrate tumors. Accordingly, labeled immune cells may be administered for the purpose of visualizing tumors. Technology disclosed herein may be applied to studies of animal models of 5 human diseases. Various animal models of diseases may evince altered dynamics or survival of one or more cell populations. Such cell populations may be labeled, administered to the animal and monitored. For example, the infiltration of immune cells into the pancreas of the NOD mouse model for diabetes may be monitored. Other examples of animal models include: experimental allergic encephalomyelitis 10 (multiple sclerosis model), gliosarcoma tumor models, and organ-transplant -rejection. By tracking phenotypically-defined populations of immune cells in these models, one can elucidate aspects of the disease etiology and monitor how cell trafficking is affected by therapeutics. This method may be used, for example, to screen for drugs that have a desired effect in an animal model. A drug screening 15 assay may comprise administering labeled cells to an animal and detecting the cells in vivo in the presence of a test agent. Changes in cell behavior that are correlated with the presence of the test agent may be indicative of a therapeutic effect. Such changes may be detected by comparison to a suitable reference, including, for example, the same animal before and after treatment with the test agent or a 20 separate, untreated animal. In addition to a test agent, the methods may be used to evaluate the effects of test conditions, such as an exercise regimen, injury, genetic alteration, etc. As an example, it is expected that a drug for treatment of an autoimmune disease would decrease the tendency of immune cells to accumulate in an affected tissue. In addition to steady state evaluations, methods disclosed herein 25 may be used to evaluate kinetic properties of cells, such as the rate at which cells arrive at a particular site and the time of signal persistence at a site. Drug screening assays may be particularly powerful when combined with in vivo monitoring of tightly defined cell populations, such as certain groups of immune cells that are implicated in various disorders. For example, monitoring of labeled cytotoxic T 30 cells may be particularly useful in identifying drugs that may be useful in preventing transplant rejection. The ability to monitor cells in vivo provides a powerful assay that may be applied to the analysis of essentially any experimental animal, WO 2007/120911 PCT/US2007/009391 24 including, for example, any of the various transgenic or otherwise mutant mice that have been generated. Several groups have studied labeling and visualizing immune cells using MRI contrast agents. Other researchers have used MRI contrast agents to label cell 5 types such as stem cells and neuronal precursors. The majority of these studies render the cells magnetically-distinct via the incorporation superparamagnetic iron oxide (SPIO) agents. Cells labeled with contrast agents incorporating other types of metal ions, particularly gadolinium and manganese have also been used. In studies utilizing these metal-ion based agents, the compounds are not directly imaged; 10 instead, one observes their indirect effect on surrounding waters. The presence of the agent tends to shorten the relaxation times (Ti, T 2 , or T 2 *) of water in proximity to the compound; these effects can be detected in relaxation time-weighted images. SPIO agents, for example, impart contrast to conventional 'H images by locally perturbing the magnetic field experienced by the nearby mobile water molecules, 15 which in turn modulates T1, T 2 , or T 2 *. Methods described herein are distinctly different from all methods using metal ion based contrast agents because signals from 1F nuclei in the imaging reagents may be directly detected and, optionally, imaged. An inherent drawback to detecting labeled cells using metal-ion based 20 contrast agents is that one is often in a situation where it is necessary to interpret subtle changes in grayscale contrast in regions that are believed to contain labeled cells. The large 'H background signal from the high concentration of mobile water present in tissues can make it difficult to unambiguously identify regions containing labeled cells; this is especially problematic if the labeled cell biodistribution is not 25 known a priori. The results of a 'snapshot' image are often ambiguous as to whether labeled cells are present in a specific tissue. This is a particularly vexing problem when trying to detect SPIO labeled cells in iron-laden organs that intrinsically appear dark in anatomical (T 2 -or T 2 *-weighted) images, such as in the liver or the spleen. Often one must resort to detecting the time-lapse image intensity 30 changes in a particular organ over a period of several hours to verify that labeled cells have accumulated. Furthermore, quantification of labeled cells in vivo in WO 2007/120911 PCT/US2007/009391 25 regions of interest using metal-ion based contrast agents is problematic, and there is generally no simple and reliable way to do this using relaxation-time weighted MRI or by using quantitative relaxation-time MRI maps. Thus the methods and compositions disclosed herein provide much needed 5 tools in the fields of medicine and biology. 2. Imaging Reagents and Formulations The imaging reagent used in the subject methods is a fluorocarbon, i.e., a molecule including at least one carbon-fluorine bond. By virtue of the 19F atoms, 10 the imaging reagents disclosed herein may be detected by 19 F MRI and other nuclear magnetic resonance techniques, such as MRS techniques. In certain preferred embodiments, a fluorocarbon imaging reagent will have one or more of the following properties: 1) reduced cytotoxicity; 2) a ' 9 F NMR spectrum that is simple, ideally having a single, narrow resonance to minimize chemical shift artifacts; 3) 15 high sensitivity with a large number of NMR-equivalent fluorine atoms in each molecule; 4) formulated to permit efficient labeling of many cell types and not restricted to phagocytic cells. Exemplary compounds include aryl or heteroaryl trifluoromethyl sulfonic acid esters (triflates) or sulfonamides (triflamides), esters of fluorinated alcohols 20 (such as 2,2,2-trifluoroethanol, perfluoro-tert-butanol, and 2,2,3,3,3 pentafluoropropanol), esters and amides of perfluoroalkanoic acids (such as trifluoroacetic acid, perfluorotetradecanoic acid, and nonafluoropentanoic acid), ethers of perfluoroalkanes, and the like. Preferably, the imaging reagent comprises a plurality of fluorines bound to carbon, e.g., greater than 5, greater than 10, greater 25 than 15 or greater than 20 fluorines bound to carbon. Preferably, at least 4, at least 8, at least 12 or at least 16 of the fluorines have a roughly equivalent NMR chemical shift. In certain embodiments, the imaging reagent is a perfluoro crown ether, such as perfluoro- 15-crown-5, perfluoro- 1 8-crown-6, perfluoro- 1 2-crown-4, etc., also 30 referred to herein as cyclic perfluoropolyethers (cyclic PFPEs). Such compounds WO 2007/120911 PCT/US2007/009391 26 are advantageous in that the 19F nuclei of these molecules will have similar or identical NMR resonances, resulting in a higher signal-to-noise ratio image with an absence of chemical-shift image artifacts. The macrocycle perfluoro-15-crown-5 ether has particularly preferable characteristics. It is neither lipophilic nor 5 hydrophilic, which is typical for perfluoropolyethers, and is emulsified into aqueous solution. Typical emulsions are small particulates (-10-500 nm diameter) that are stable in aqueous solution and can be taken up by cells. One of skill in the art will recognize, that other fluorinated compounds will have desirable properties, particularly those fluorinate compounds in which each fluorine atom is in a similar 10 chemical environment. Esters of perfluoro-tert-butanol, 1,3,5 tris(trifluoromethyl)benzene, hexafluoroacetone, poly(trifluoromethylethylene), and perfluorocyclohexane are examples of compounds. having multiple fluorine atoms with 1 9 F resonances that have the same, or nearly the same, Larmor frequencies. In certain embodiments, the imaging reagent is a polymer. In certain 15 embodiments, the imaging reagent is or includes a linear perfluoropolyether (linear PFPE), e.g., a compound having a structure or portion thereof comprising repeated units of -[O-CF 2
(CF
2 )xCF 2 ]n-, where x is an integer from 0 to 10, preferably from 0 3, and n is an integer from 2 to 100, preferably from 4 to 40. Perfluorinated linear polyethylene oxide, for example, can be obtained from Exfluor Corp. (Round Rock, 20 TX). Either or both ends (or a plurality of ends, in the case of branched polymers) may be derivatized with a moiety that provides an additional desired functionality. For example, an imaging reagent may have a formula of A-B-C, where A and/or C may be a functional moiety and B comprises repeated units of-[O-CF 2
(CF
2 )xCF 2 ]n-, where x is an integer from 0 to 10, preferably from 0-3, and n is an integer from 2 to 25 100, preferably from 4 to 40. Functional moieties (e.g., non-fluorinated monomers conferring a particular desired function) are discussed further below. A linear perfluoropolyether may also be described as a composition having the average formula: XO(Y-O)nZ 30 wherein Y is selected from the group comprising: WO 2007/120911 PCT/US2007/009391 27 F F F F F I I I I I and. F F F F F F F F F -C-C- C--C F F F F wherein n is an integer from 8 to 30; wherein X and Z are the same and are selected from the group comprising: perfluoroalkyls, perfluoroethers, fluoroalkyls terminated with fluoroacyl, carboxyl, amide or ester, methylols, acid chlorides, amides, 5 amidines, acrylates and esters, as well as any of the preceding derivatized with a functional moiety. While a completely fluorinated polymer can be formed, for example, by reacting a perfluorinated diacid with a perfluorinated dihalocarbon (such as 1,4 diiodooctafluorobutane), fluorinated monomers can be reacted with other monomers 10 (optionally functional moieties, which may be non-fluorinated) to form hybrid polymers that are useful as imaging reagents. A variety of different non-fluorinated monomers can be used to vary the chemical and physical properties of the overall polymer, and make it possible to tailor the imaging reagent for specific uses. For example, a highly lipophilic imaging reagent may concentrate in cultured cells that 15 will be destined for a patient as part of a cellular therapeutic. For labeling cells in culture, the imaging reagents can be employed in one or more of at least three modalities: 1) imaging reagents that are internalized or otherwise absorbed by target cells without the formation of any covalent or other binding association; 2) imaging reagents that covalently attach to target cells; and 3) 20 imaging reagents coupled to molecules, such as antibodies or ligands, that bind to molecules present on the target cells. Imaging reagents of the first type include the perfluoro crown ethers and other PFPEs that are taken up by cells and, preferably, are retained in the cell without degradation for a substantial period of time, e.g., having a half-life in the WO 2007/120911 PCT/US2007/009391 28 cell of at least 1 hour, at least 4 hours, at least about a day, at least about three days, or even at least about a week. For obvious reasons, it is preferred that the imaging reagent not interfere with ordinary cellular functions or exhibit cytotoxicity at the concentrations employed for labeling. As demonstrated herein, perfluoropolyethers 5 show reduced toxic effect on the labeled cells. Imaging reagents of the second type include electrophilic compounds that react with nucleophilic sites on the cell surface, such as exposed thiol, amino, and/or hydroxyl groups. Accordingly, imaging reagents such as maleimides, alkyl iodides, N-hydroxysuccinimide or N-hydroxysulfosuccinimide esters (NHS or sulfo-NHS 10 esters), acyl succinimides, and the like can form covalent bonds with cell surfaces. Other techniques used in protein coupling can be adapted for coupling imaging reagents to cell surface proteins. See Means et al. (1990) Bioconiugate Chemistry 1:2-12, for additional approaches to such coupling. Imaging reagents of the third type can be prepared by reacting imaging 15 reagents of the second type not with the cells themselves, but with a functional moiety that is a cell-targeting ligand or antibody. Suitable ligands and antibodies can be selected for the application of interest. For example, a ligand that selectively targets hematopoietic cells could be labeled with an imaging reagent as described herein and administered to a patient, such as by injection. 20 Alternatively, an imaging reagent can be coupled to an indiscriminate internalizing peptide, such as antepennepedia protein, HIV transactivating (TAT) protein, mastoparan, melittin, bombolittin, delta hemolysin, pardaxin, Pseudomonas exotoxin A, clathrin, Diphtheria toxin, C9 complement protein, or a fragment of any of these. Cells treated with this indiscriminate molecule ex vivo will absorb the 25 imaging reagent. When such labeled cells are implanted into an animal, such as a mammal, the imaging reagent can be used to visualize and/or track the implanted cells by nuclear magnetic resonance techniques. In one embodiment, the internalizing peptide is derived from the drosophila antepennepedia protein, or homologs thereof. The 60-amino acid-long 30 homeodomain of the homeo-protein antepennepedia has been demonstrated to WO 2007/120911 PCT/US2007/009391 29 translocate through biological membranes and can facilitate the translocation of heterologous polypeptides to which it is coupled. See for example Derossi et al. (1994) JBiol Chem 269:10444-10450; and Perez et al. (1992) J Cell Sci 102:717 722. It has been demonstrated that fragments as small as 16 amino acids long of this 5 protein are sufficient to drive internalization. See Derossi et al. (1996) JBiol Chem 271:18188-18193. Another example of an internalizing peptide is the HIV transactivator (TAT) protein. This protein appears to be divided into four domains (Kuppuswamy et al. (1989) Nucl. Acids Res. 17:3551-3561). Purified TAT protein is taken up by cells in 10 tissue culture (Frankel and Pabo, (1989) Cell 55:1189-1193), and peptides, such as the fragment corresponding to residues 37 -62 of TAT, are rapidly taken up by cell in vitro (Green and Loewenstein, (1989) Cell 55:1179-1188). The highly basic region mediates internalization and targeting of the internalizing moiety to the nucleus (Ruben et al., (1989) J. Virol. 63:1-8). Peptides or analogs that include a 15 sequence present in the highly basic region can be conjugated to fluorinated imaging reagents to aid in internalization and targeting those reagents to the intracellular milieu. Another PFPE composition of interest is linear PFPEs (structure shown above) derivatized with a variety of end groups. The linear compounds have the 20 advantage that one can conjugate a variety of functional entities to the end groups, such as functional moieties of various types. The 'F NMR spectra of these linear compounds generally is more complex than the macrocyclic compounds, but a PFPE with two well-separated NMR signals can also be used. In this case it may be desirable to use an MRI pulse sequence that incorporates one or more off-resonance 25 saturation pulses applied to the smaller resonance to eliminate any chemical shift artifacts. A particularly useful application of linear PFPEs is the synthesis of a "dual mode" agent that can be detected by ' 9 F nuclear magnetic resonance techniques and includes a detection moiety that facilitates detection by a second detection method. 30 As an example, a fluorescent moiety attached to the endgroups may be used to generate imaging reagents that can be visualized with 1 9 F MRI and fluorescence WO 2007/120911 PCT/US2007/009391 30 microscopy. A wide range of fluorescent moieties may be used in a dual-mode agent. Many suitable fluorophores are known, including fluorescein, lissamine, phycoerythrin, rhodamine (Perkin Elmer Cetus), Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, FluorX (Amersham), and Alexa dyes (Molecular Probes) . Fluorescent moieties 5 include derivatives of fluorescein, benzoxadioazole, coumarin, eosin, Lucifer Yellow, pyridyloxazole and rhodamine. These and many other exemplary fluorescent moieties may be found in the Handbook of Fluorescent Probes and Research Chemicals (2000, Molecular Probes, Inc.). Additional fluorescent moieties include fluorescent nanocrystals, such as the "quantum dot" products available from 10 Quantum Dot Corporation (Hayward, Calif.). Such nanocrystals may be constructed with a semiconductor core having an appropriate emission spectrum (e.g., CdS, CdSe, CdTe), a shell composed of a non-emissive transparent and relatively non reactive material that can be efficiently wed to the underlying core material (e.g., ZnS), and a coating that provides desirable solubility (e.g., for solubility in aqueous, 15 physiological solutions) and possible reactive groups for attachment to a fluorocarbon described herein. Dual mode imaging reagents that permit fluorescent detection are particularly useful in a variety of applications. For example, fluorescent labeling permits the use of fluorescence-based cell sorting mechanisms, such as Fluorescence 20 Activated Cell Sorting (FACS). Cell sorting may be desirable, for example, to enrich for a population of cells that have been successfully labeled. This may be particularly useful where labeling has been directed to rarer cell populations. Dual mode agents are also useful for finding and characterizing labeled cells after they have been implanted into a living subject. In this application, cells may be biopsied, 25 or by some other means harvested, from the subject after they have resided there for some duration. Biological analysis of the harvested cells can then be performed. For example, FACS analysis can be performed on the harvested cells, where after positively selecting cells for the fluorescent PFPE label, the cells can be assayed for the expression of specific cell surface markers (using a different color fluorescent 30 probe) to investigate any change in cell phenotype that occurred following implantation. Fluorescent labels may also be used for fluorescence microscopy of cells, particularly using three-dimensional confocal fluorescence microscopy.
WO 2007/120911 PCT/US2007/009391 31 Fluorescence microscopy will not generally be useful for in vivo visualization of deep tissues containing labeled cells, but surface tissues may be visualized as well as tissue samples. Dual labeling will be particularly valuable in calibrating and validating any new fluorocarbon-based nuclear magnetic resonance labeling method. 5 Results obtained by, for example, MRI/MRS may be compared to those obtained by fluorescence detection, both in cultured labeled cells (biopsied or otherwise) and in vivo, to the extent possible. A known fluorescence signal strength per unit molecule may be used to calibrate MRI/MRS measurements. Detection moieties suitable for PET imaging may also be used to create dual 10 mode imaging reagents that are detectable by nuclear magnetic resonance techniques and by PET techniques. For example, the 18F isotope is a potent label for PET detection methods. A fluorocarbon imaging reagent may comprise a mixture of ' 8 F and 1 9 F isotopes, thus providing a dual mode label that is suitable for MRI/MRS and PET. I 8F and "F may also be added in separate monomers to form a mixed 15 copolymer, or ' 8 F portions may be located at either end of a linear polyether, at the position where most other functional moieties would be added. ' 8 F has no NMR signal and so may be added at positions that would, for example, tend to decrease NMR linewidth, simplify the NMR spectrum, or alleviate chemical shifts from resonances that adversely affect the read-out obtained by a nuclear magnetic 20 resonance technique. In addition, molecules of the fluorocarbon imaging reagents can incorporate other radioisotopes that are effective PET probes, such as "IC, ISO, and 1 3 N. Those skilled in the art can, in view of this specification, devise many other 'PET-detectable moieties that can be incorporated into or, for example, attached to an endgroup(s), of the imaging reagents of this disclosure. 25 In certain embodiments, a linear perfluoropolyether may be derivatized with a relatively hydrophilic moiety at one, or preferably, both ends. For example, the hydrophilic moiety may be a polyethylene glycol, thus forming a tri-block copolymer with water-soluble regions on each end and a hydrophobic region in the center. When mixed in an aqueous environment, imaging reagents of this type will 30 tend to form micelles, with the PFPE core surrounded by a water-soluble coat. Amino-PEG blocks are commercially available with a range of molecular weights.
WO 2007/120911 PCT/US2007/009391 32 Coupling the PFPE core with other groups, such as aliphatic amines and phosphatidyl ethanolamine in place of the hydrophilic sections, will give derivatives with different solubility characteristics (see W02005072780). In certain embodiments, the disclosure provides formulations of imaging 5 reagents that are suitable for uptake by cells. Optionally, an imaging reagent may be formulated as an emulsion. For example, in a preferred embodiment, a label formulation comprises a 1:1 molar ratio of PFPE with Pluronic L-35 or F68. Emulsions including a fluorocarbon imaging reagent, such as a PFPE, will preferably have a distribution of particle sizes that allow adequate cellular uptake. 10 In certain embodiments, a uniform particle size may be advantageous. The desired degree of uniformity of particle size may vary depending upon the application. For example, it will generally be desirable that the mean particle size fall within a range from 10 nm to 500 nm, and preferably a range of from 30 nm to 150 nm or a range of from about 350 to 500 nm. Optionally, 25%, 50%, 75% or more of the particles 15 will also fall within the selected range. Particle sizes may be evaluated by, for example, light scattering techniques or by visualizing the emulsion particles using EM micrographs. In certain cell types that have a relatively small amount of cytoplasm, such as most stem cells, preferred particle sizes will be in the range of 10-50 nm in diameter, and optionally 100-200 nm diameter. 20 Emulsions for use in cells should preferably be stable at a wide range of temperatures. Preferred emulsions will be stable at body temperature (37*C for humans) and at a storage temperature, such as 40C or room temperature (20-25*C). For example, it will often be desirable to store the emulsion at a cool temperature, in the range of 2 - 10*C, and preferably 4"C, and then warm the emulsion to room 25 temperature (e.g., 18 to 28"C, and more typically 20 to 25"C). After labeling of cells, the emulsion will experience a temperature of about 37"C. Accordingly, a preferred emulsion will retain the desired range of particle sizes at temperatures ranging from refrigeration temperatures up to body temperature. The properties of an emulsion may be controlled primarily by the properties 30 of the imaging reagent itself, the nature of surfactants and/or solvents used, and the type of processing device (e.g., sonicator, Microfluidizer, homogenizer, etc.).
WO 2007/120911 PCT/US2007/009391 33 Methods for forming PFPE emulsions are extensively described in U.S. Pat. Nos. 5,330,681 and 4,990,283. A continuous phase of a polyhydroxylated compound, such as polyalcohols and saccharides in concentrated aqueous solution may be effective. The following polyalcohols and saccharides have proved to be 5 particularly effective: glycerol, xylitol, mannitol, sorbitol, glucose, fructose, saccharose, maltitol, dimer compounds of glycerol (di-glycerol or bis(2,3-di hydroxypropyl) ether, solid water soluble polyhydroxylated compounds as sugars and glycerol condensation products as triglycerol and tetraglycerol. The dispersion in emulsion may be performed in the presence of conventional surfactants, including 10 cationic, anionic, amphoteric and non-ionic surfactants, with ionic surfactants being preferable. Examples of suitable surfactants include sodium lauryl sulphate, sulphosuccinate (sulphosuccinic hemiester), coco-amphocarboxyglycinate, potassium cetyl phosphate, sodium alkyl-polyoxyethylene-ether carboxylate, potassium benzalconium chloride, alkyl amidopropyl betaine, cetyl-stearilic 15 ethoxylated alcohol, and sorbitan-ethoxylate(20)-mono-oleate Tween 20. While thermodynamic equations may be used to attempt to predict mixtures of imaging reagents that will give emulsions having the desired particle sizes and stability, it is generally accepted that actual testing of various mixtures will be most effective. The emulsification of mixtures is simple and quick, permitting rapid testing of a 20 wide range of combinations to identify those that give rise to emulsions that are suitable for use in the methods disclosed herein. Preferably an emulsion is designed to facilitate uptake of the imaging reagent by the subject cells. A surfactant may be designed to form stable emulsions that carry a large quantity of PFPE into the aqueous phase. Additionally, it may have 25 properties that increase the intracellular delivery of the emulsion particles in the shortest possible incubation time. Increasing the PFPE intracellular loading improves sensitivity to the labeled cells. Furthermore, minimizing the culture time can be important when working with the primary cells cultures. The efficiency of intracellular uptake depends on cell type. For example macrophages and some 30 dendritic cells will endocytose almost any particulate, whereas other cell types of interest may only be weakly phagocytic. In either case the uptake efficiency can be boosted substantially by designing the surfactant so that the surface of the emulsion WO 2007/120911 PCT/US2007/009391 34 particle has properties that promote cellular uptake in culture (i.e. "self-delivering" emulsion particles). The emulsion particle surface can be made to have lipophilic, or optionally cationic, properties via appropriate surfactant design. For example the surfactant can incorporate lipids, such as cationic lipids, oil-in-water emulsions, 5 micelles, mixed micelles, or liposomes, that tend to bind to or fuse with the cell's surface, thereby enhancing emulsion particle uptake. A preferred colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (i.e., an artificial membrane vesicle). The preparation and use of such systems is well known in the art. Suitable cationic lipids are described in the following and are herein 10 incorporated in their entirety: Felgner et al., 1987, PNAS 84, 7413-7417; Eppstein et al., U.S. Pat. No. 4,897,355), (Rose, U.S. Pat. No. 5,279,833; Eppand et al. U.S. Pat. No. 5,283,185; Gebeyehu et al., U.S. Pat. No. 5,334,761; Nantz et al., U.S. Pat. No. 5,527,928; Bailey et al., U.S. Pat. No. 5,552,155; Jesse, U.S. Pat. No. 5,578,475). Other approaches include incorporation into the surfactant peptides (e.g. oligo-Arg9 15 and TAT-like peptides) that facilitate entry into cells, or antibodies that target specific cell surface molecules. Additionally, in certain embodiments, one can incorporate small cationic proteins into the surfactant, such as protamine sulfate, to enhance cellular uptake. Protamine sulfate is non-toxic to cells and has FDA approval for use in humans as a heparin antagonist. In certain embodiments, 20 colloidal dispersion systems are used, such as macromolecule complexes, nanocapsules, microspheres, and beads. Other approaches for enhancing uptake of the emulsified fluorocarbons, such as by using additional transfection agents or by using electroporation of the cells, is described herein. In preferred embodiments, emulsions have "self-delivering" properties 25 without having to add uptake enhancing reagents. Said emulsions are preferably stable and have a shelf-life of a period of months or years. It is understood that surfactants and uptake enhancing reagents are not meant to be exclusive groups and in some cases they may be overlapping.
WO 2007/120911 PCT/US2007/009391 35 3. Cells and Labeling Methods described herein may be used with a wide range of cells, including both prokaryotic and eukaryotic cells, and preferably mammalian cells. Technologies for cell preparation include cell culture, cloning, nuclear transfer, 5 genetic modification and encapsulation. A partial list of suitable mammalian cells includes: blood cells, myoblasts, bone marrow cells, peripheral blood cells, umbilical cord blood cells, cardiomyocytes (and precursors thereof), chondrocytes (cartilage cells), dendritic cells, fetal neural tissue, fibroblasts, hepatocytes (liver cells), islet cells of pancreas, 10 keratinocytes (skin cells) and stem cells. In certain preferred embodiments, the cells to be used are a fractionated population of immune cells. Recognized subpopulations of immune cells include the lymphocytes, such as B lymphocytes (Fc receptors, MHC class II, CD19+, CD21+), helper T lymphocytes (CD3+, CD4+, CD8-), cytolytic T lymphocytes (CD3+, CD4-, CD8+), natural killer cells (CD16+), 15 the mononuclear phagocytes, including monocytes, neutrophils and macrophages, and dendritic cells. Other cell types that may be of interest include eosinophils and basophils. Cells may be autologous (i.e., derived from the same individual) or syngeneic (i.e., derived from a genetically identical individual, such as a syngeneic 20 littermate or an identical twin), although allogeneic cells (i.e., cells derived from a genetically different individual of the same species) are also contemplated. Although less preferred, xenogeneic (i.e., derived from a different species than the recipient) cells, such as cells from transgenic pigs, may also be administered. When the donor cells are xenogeneic, it is preferred that the cells are obtained from an individual of a 25 species within the same order, more preferably the same superfamily or family (e.g. when the recipient is a human, it is preferred that the cells are derived from a primate, more preferably a member of the superfamily Hominoidea). Cells may, where medically and ethically appropriate, be obtained from any stage of development of the donor individual, including prenatal (e.g., embryonic or 30 fetal), infant (e.g., from birth to approximately three years of age in humans), child WO 2007/120911 PCT/US2007/009391 36 (e.g.. from about three years of age to about 13 years of age in humans), adolescent (e.g., from about 13 years of age to about 18 years of age in humans), young adult (e.g., from about 18 years of age to about 35 years of age in humans), adult (from about 35 years of age to about 55 years of age in humans) or elderly (e.g., from 5 about 55 years and beyond of age in humans). In many embodiments, cells are labeled by contacting the cells with an emulsion of the imaging reagent, such that the reagent is taken up by cells. Both phagocytic and non-phagocytic cells may be labeled by such a method. For example, as demonstrated in W02005072780, both dendritic cells (phagocytic) and 10 gliosarcoma cells (non-phagocytic) can be labeled by contacting the cells with an emulsion of the imaging reagent. In certain embodiments the cells to be labeled are stem cells. Stem cell therapies are commonly used as part of an ablative regimen for treatment of cancer with high dose radiation and/or chemotherapeutic agents. Ablative regimens 15 generally employ hematopoietic stem cells, or populations of cells containing hematopoietic stem cells, as may be obtained, for example, from peripheral blood, umbilical cord blood or bone marrow. Cells of this type, or a portion thereof, may be labeled and tracked in vivo to monitor survival and engraftment at the appropriate location. Other types of stem cells are increasingly attractive as therapeutic agents 20 for a wide variety of disorders. As an example, cells may be mouse embryonic stem cells, or ES cells from another model animal. The labeling of such cells may be useful in tracking the fate of such cells administered to mice, optionally as part of a preclinical research program for developing embryonic stem cell therapeutics. Examples of mouse 25 embryonic stem cells include: the JMI ES cell line described in M. Qiu et al., Genes Dev 9, 2523 (1995), and the ROSA line described in G. Friedrich, P. Soriano, Genes Dev 5, 1513 (1991), and mouse ES cells described in US Patent No. 6,190,910. Many other mouse ES lines are available from Jackson Laboratories (Bar Harbor, Maine). Examples of human embryonic stem cells include those available through 30 the following suppliers: Arcos Bioscience, Inc., Foster City, California, CyThera, Inc., San Diego, California, BresaGen, Inc., Athens, Georgia, ES Cell International, WO 2007/120911 PCT/US2007/009391 37 Melbourne, Australia, Geron Corporation, Menlo Park, California, Goteborg University, G6teborg, Sweden, Karolinska Institute, Stockholm, Sweden, Maria Biotech Co. Ltd. - Maria Infertility Hospital Medical Institute, Seoul, Korea, MizMedi Hospital - Seoul National University, Seoul, Korea, National Centre for 5 Biological Sciences/ Tata Institute of Fundamental Research, Bangalore, India, Pochon CHA University, Seoul, Korea, Reliance Life Sciences, Mumbai, India, ReNeuron, Surrey, United Kingdom, StemCells, Inc., Palo Alto, California, Technion University, Haifa, Israel, University of California, San Francisco, California, and Wisconsin Alumni Research Foundation, Madison, Wisconsin. In 10 addition, examples of embryonic stem cells are described in the following U.S. patents and published patent applications: 6,245,566; 6,200,806; 6,090,622; 6,331,406; 6,090,622; 5,843,780; 20020045259; 20020068045. In preferred embodiments, the human ES cells are selected from the list of approved cell lines provided by the National Institutes of Health and accessible at http://escr.nih.gov. In 15 certain preferred embodiments, an embryonic stem cell line is selected from the group comprising: the WA09 line obtained from Dr. J. Thomson (Univ. of Wisconsin) and the UC01 and UC06 lines, both on the current NIH registry. In certain embodiments, a stem cell for use in disclosed methods is a stem cell of neural or neuroendocrine origin, such as a stem cell from the central nervous 20 system (see, for example US Patent Nos. 6,468,794; 6,040,180; 5,753,506; 5,766,948), neural crest (see, for example, US Patent Nos. 5,589,376; 5,824, 489), the olfactory bulb or peripheral neural tissues (see, for example, Published US Patent Applications 20030003574; 20020123143; 20020016002 and Gritti et al. 2002 J Neurosci 22(2):437-45), the spinal cord (see, for example, US Patent Nos. 25 6,361,996, 5,851,832) or a neuroendocrine lineage, such as the adrenal gland, pituitary gland or certain portions of the gut (see, for example, US Patent Nos. 6,171,610 and PC12 cells as described in Kimura et al. 1994 J. Biol. Chem. 269; 18961-67). In preferred embodiments, a neural stem cell is obtained from a peripheral tissue or an easily healed tissue, thereby providing an autologous 30 population of cells for transplant.
WO 2007/120911 PCT/US2007/009391 38 Hematopoietic or mesenchymal stem cells may be employed in certain disclosed methods. Recent studies suggest that marrow-derived hematopoietic (HSCs) and mesenchymal stem cells (MSCs), which are readily isolated, have a broader differentiation potential than previously recognized. Purified HSCs not only 5 give rise to all cells in blood, but can also develop into cells normally derived from endoderm, like hepatocytes (Krause et al., 2001, Cell 105: 369-77; Lagasse et al., 2000 Nat Med 6: 1229-34). Similarly, HSCs from peripheral blood and from umbilical cord blood are expected to provide a useful spectrum of developmental potential. MSCs appear to be similarly multipotent, producing progeny that can, for 10 example, express neural cell markers (Pittenger et al., 1999 Science 284: 143-7; Zhao et al., 2002 Exp Neurol 174: 11-20). Examples of hematopoietic stem cells include those described in US Patent Nos. 4,714,680; 5,061,620; 5,437,994; 5,914,108; 5,925,567; 5,763,197; 5,750,397; 5,716,827; 5,643,741; 5,061,620. Examples of mesenchymal stem cells include those described in US Patent Nos. 15 5,486,359; 5,827,735; 5,942,225; 5,972,703, those described in PCT publication nos. WO 00/53795; WO 00/02654; WO 98/20907, and those described in Pittenger et al. and Zhao et al., supra. Stem cell lines are preferably derived from mammals, such as rodents (e.g. mouse or rat), primates (e.g. monkeys, chimpanzees or humans), pigs, and ruminants 20 (e.g. cows, sheep and goats), and particularly from humans. In certain embodiments, stem cells are derived from an autologous source or an HLA-type matched source. For example, stem cells may be obtained from a subject in need of pancreatic hormone-producing cells (e.g. diabetic patients in need of insulin producing cells) and cultured to generate autologous insulin-producing cells. Other 25 sources of stem cells are easily obtained from a subject, such as stem cells from muscle tissue, stem cells from skin (dermis or epidermis) and stem cells from fat. In some preferred embodiments, cells for administration to a human should be compliant with good tissue practice guidelines set by the U.S. Food and Drug Administration (FDA) or equivalent regulatory agency in another country. Methods 30 to develop such a cell line may include donor testing, and avoidance of exposure to non-human cells and products.
WO 2007/120911 PCT/US2007/009391 39 Cells derived from a donor (optionally the patient is the donor) may be administered as unfractionated or fractionated cells, as dictated by the purpose of the cells to be delivered. Cells may be fractionated to enrich for certain cell types prior to administration. Methods of fractionation are well known in the art, and generally 5 involve both positive selection (i.e., retention of cells based on a particular property) and negative selection (i. e., elimination of cells based on a particular property). As will be apparent to one of skill in the art, the particular properties (e.g., surface markers) that are used for positive and negative selection will depend on the desired population of cells. Methods used for selection/enrichment of cells may include 10 immunoaffinity technology or density centrifugation methods. Immunoaffinity technology may take a variety of forms, as is well known in the art, but generally utilizes an antibody or antibody derivative in combination with some type of segregation technology. The segregation technology generally results in physical segregation of cells bound by the antibody and cells not bound by the antibody, 15 although in some instances the segregation technology which kills the cells bound by the antibody may be used for negative selection. Any suitable immunoaffinity technology may be utilized for selection/enrichment of the selected cells to be used, including fluorescence activated cell sorting faces) , panning, immunomagnetic separation, 20 immunoaffinity chromatography, antibody-mediated complement fixation, immunotoxin, density gradient segregation, and the like. After processing in the immunoaffinity process, the desired cells (the cells bound by the immunoaffinity reagent in the case of positive selection, and cells not bound by the immunoaffinity reagent in the case of negative selection) are collected and either subjected to further 25 rounds of immunoaffinity selection/enrichment, or reserved for administration to the patient. Immunoaffinity selection/enrichment is typically carried out by incubating a preparation of cells comprising the desired cell type with an antibody or antibody derived affinity reagent (e.g., an antibody specific for a given surface marker), then 30 utilizing the bound affinity reagent to select either for or against the cells to which the antibody is bound. The selection process generally involves a physical WO 2007/120911 PCT/US2007/009391 40 separation, such as can be accomplished by directing droplets containing single cells into different containers depending on the presence or absence of bound affinity reagent faces) , by utilizing an antibody bound (directly or indirectly) to a solid phase substrate (panning, immunoaffinity chromatography), or by utilizing a 5 magnetic field to collect the cells which are bound to magnetic particles via the affinity reagent (immunomagnetic separation). Alternately, undesirable cells may be eliminated from the preparation using an affinity reagent which directs a cytotoxic insult to the cells bound by the affinity reagent. The cytotoxic insult may be activated by the affinity reagent (e.g., complement fixation), or may be localized to 10 the target cells by the affinity reagent (e.g., immunotoxin, such as ricin B chain). Although it is expected that methods disclosed herein will be frequently used for in vivo monitoring of cells, it should be noted that the methodologies are equally effective for the monitoring of cells in culture, in a tissue sample or other ex vivo cellular material. For therapeutic uses, cells may be labeled at a desired step during 15 the preparation for administration to the patient. A variety of methods may be used to label cells with imaging reagent. In general, cells will be placed in contact with imaging reagent such that the imaging reagent becomes associated with the cell. Conditions will often be standard cell culture conditions designed to maintain cell viability. The term "associated" is 20 intended to, encompass any manner by which the imaging reagent and cell remain in sufficiently close physical proximity for a sufficient amount of time as to allow the imaging reagent to provide useful information about the position of the cell, whether in vivo or in vitro. Imaging reagent may be located intracellularly, e.g. after phagocytosis or surfactant mediated entry into the cell. Immune cells, such as 25 dendritic cells, macrophages and T cells are often highly phagocytic and data presented herein and in other studies demonstrate that such cells, and other phagocytic cell types, are readily labeled. Other cell types, such as stem cells may also be labeled, regardless of phagocytic activity. Imaging reagent may be inserted into a cell membrane or covalently or non-covalently bound to an extracellular 30 component of the cell. For example, certain linear fluorocarbons described herein may be derivatized to attach one or more targeting moiety. A targeting moiety will WO 2007/120911 PCT/US2007/009391 41 be selected to facilitate association of the imaging reagent with the cell to be labeled. A targeting moiety may be designed to cause non-specific insertion of the fluorocarbon into a cell membrane (e.g., a hydrophobic amino acid sequence or other hydrophobic moiety such as a palmitoyl moiety or myristoyl moiety) or to 5 facilitate non-specific entry into the cell. A targeting moiety may bind to a cell surface component, as in the case of receptor ligands. A targeting moiety may be a member of a specific binding pair, where the partner is a cell surface component. The targeting moiety may be, for example, a ligand for a receptor, or an antibody, such as a monoclonal or polyclonal antibody or any of the various polypeptide 10 binding agents comprising a variable portion of an immunoglobulin (e.g., Fv fragment, single chain Fv (scFv) fragment, Fab' fragment, F(ab')2 fragment, single domain antibody, camelized antibody, humanized antibody, diabodies, tribodies, tetrabodies). Cellular labeling with fluorocarbons emulsions can also be facilitated using 15 transfection agents to aid in cell delivery. Often transfection agents consist of cationic lipids, cationic liposomes, poly-cations, and the like. The transfection agent is pre-mixed with the fluorocarbon emulsion labeling agent, whereby it becomes associated with, or coats, the emulsion particles. The transfection agent-treated emulsion particles are then added to the cultured cells and incubated so that the cells 20 become labeled. Common transfection agents include Lipofectamine (Invitrogen, Inc) FuGene, DOTAP (Roche Diagnostics, Inc.), and poly-L-lysine. Small proteins can also be used as transfection agents, such as many types of protamines. Protamines, the major DNA-binding proteins in the nucleus of sperm in most vertebrates, package the DNA in a volume less than 5% of a somatic cell nucleus. 25 Protamines are simple proteins of low molecular weight that are rich in arginine and strongly basic. Commercially available protamines come from the sperm of salmon and certain other species of fish. The term "protamine" as used herein, refers to a low molecular weight cationic, arginine-rich polypeptide. The protamine molecule typically comprises about 20 to about 200 amino acids and is generally characterized 30 by containing at least 20%, 50% or 70% arginine. Protamines are often formulated as salts, with one or more counter ions such as sulfate, phosphate and chloride.
WO 2007/120911 PCT/US2007/009391 42 Data provided in this application show that protamines (e.g., protamine sulfate) are highly effective in delivering PFPE fluorocarbon emulsion particles to cultured cells. Suitable protamine sulfates can come from a variety of sources (e.g., salmon, herring, trout, etc.) and be of various grades and forms (e.g., USP, grades II, 5 III, X, etc.), with and without histones or any recombinant derivative. Examples of other protamine solutions that may be used as transfection agents include protamine phosphate, protamine chloride, protamine sulfate-2, protamine sulfate-3, protamine sulfate-I 0, and protamine free base. Cell electroporation can also be used to deliver fluorocarbon emulsion 10 particles into cells. Electroporation has the advantage that labeling is very rapid proccess, and it does not require the use of transfection agents. Many methods of cell electroporation are know in the art for a wide range of cell types, and several commercially available electropration instruments are available (e.g., BTX, Inc., Harvard Apparatus, Inc., Amaxa Biosystems, Inc., etc. ). Electroporation is used to 15 deliver nucleic acids, molecules, and small particulates into cells in vitro. Magnetoelectorporation has been shown to be effective for MRI in cell culture (Walczak P., Magn Reson Med. 2005. Oct;54(4):769-74). Data in this application shows that cell electroporation is effective in delivering linear PFPE fluorocarbon emulsion particles into dendritic cells, and there is no barrier to using the same 20 method to fluorocarbon-label many other phagocytic and non-phagocytic cell types, such as stem cells. Where cells are to be used in a therapeutic regimen, various methods have been used to for delivery of cells including injections and use of special devices to implant cells in various organs. The present invention is not tied to any particular 25 delivery method. Data presented herein demonstrate that labeled cells may be monitored regardless of whether the cells are delivered directly to a particular site or delivered systemically. For example, labeled DCs were successfully imaged following either a focal implantation directly into tissues or an intravenous injection, and T-cells were imaged following intraperitoneal injection. Cells may be inserted 30 into a delivery device which facilitates introduction by injection or implantation into the subjects. Such delivery devices may include tubes, e.g., catheters, for injecting WO 2007/120911 PCT/US2007/009391 43 cells and fluids into the body of a recipient subject. In a preferred embodiment, the tubes additionally have a needle, e.g., a syringe, through which the cells of the disclosure can be introduced into the subject at a desired location. The cells may be prepared for delivery in a variety of different forms. For example, the cells may be 5 suspended in a solution or gel or embedded in a support matrix when contained in such a delivery device. Cells may be mixed with a pharmaceutically acceptable carrier or diluent in which the cells of the disclosure remain viable. Pharmaceutically acceptable carriers and diluents include saline, aqueous buffer solutions, solvents and/or dispersion media. The use of such carriers and diluents is 10 well known in the art. The solution is preferably sterile and fluid. Preferably, the solution is stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms such as bacteria and fungi through the use of, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. Solutions of the disclosure may be prepared by 15 incorporating cells as described herein in a pharmaceutically acceptable carrier or diluent and, as required, other ingredients enumerated above, followed by filtered sterilization. 4. Nuclear Magnetic Resonance Techniques 20 As described herein, nuclear magnetic resonance techniques may be used to detect populations of labeled cells. The term "detect" is used to include any effort to ascertain the presence or absence of a labeled molecule or cell, particularly by a nuclear magnetic resonance technique. The term "detect" is also intended to include more sophisticated measurements, including quantitative measurements and two- or 25 three-dimensional image generation. For example, MRI may be used to generate images of such cells. In many instances, the labeled cells may be administered to a living subject. Following administration of the cells, some portion of the subject, or the entire subject, may be examined by MRI to generate an MRI data set. A "data set", as the term is used herein, is intended to include raw data gathered during 30 magnetic resonance probing of the subject material, the acquisition parameters, as well as information processed, transformed or extracted from the raw data. The raw WO 2007/120911 PCT/US2007/009391 44 data includes transient signals obtained by MRI/MRS, including the free-induction decays, spin-echoes, stimulated-echoes, and/or gradient echoes. Examples of processed information include two-dimensional or three-dimensional pictorial representations of the subject material. The processed information may also include 5 magnitude images, the real and imaginary image components, as well as the associated phase map images. Another example of extracted information is a score representing the amount or concentration of imaging reagent or 1 9 F signal in the subject material. By using the amount of 1 9 F signal in the subject material, and a calibration of the mean amount of imaging reagent per cell pre-implantation, one can 10 estimate the absolute number of cells in the subject material. The amount of ' 9 F signal present in a subject material can be represented or calculated in many ways; for example, the average signal-to-noise-ratio (SNR) of the 1 9 F signal for a region of interest (ROI) may be measured and used to calculate the abundance of labeled cells. In certain embodiments, the average intensity, or pixel- or voxel-wise summation of 15 the '9F signal may be used to calculate the abundance of labeled cells. This type of data may be gathered at a single region of the subject, such as, for example, the spleen or another organ of particular relevance to the labeled cells. Labeled cells may be examined in contexts other than in the subject. It may be desirable to examine labeled cells in culture. In certain embodiments, labeled cells may be 20 applied to or generated within a tissue sample or tissue culture, and labeled cells may therefore be imaged in those contexts as well. For example, an organ, tissue or other cellular material to be transplanted may be contacted with an imaging reagent to generate labeled cells prior to implantation of such transplant in a subject. In general, labeling agents of the disclosure are designed for use in 25 conventional MRI detection systems. In the most common implementation of MRI, one observes the hydrogen nucleus (proton, 'H) in molecules of mobile water contained in subject materials. To detect labels disclosed herein, an alternate nucleus is detected, 1 9 F. ' 9 F MRI has only slightly less intrinsic sensitivity compared to 'H; the relative sensitivity is approximately 0.83. Both have a nuclear spin of +1/2. The 30 natural isotopic abundance of ' 9 F is 100%, which is comparable to 99.985% for 'H. The physical principles behind the detection and image formation are the same for both 'H and ' 9 F MRI. The subject material is placed in a large static magnetic field.
WO 2007/120911 PCT/US2007/009391 45 The field tends to align the magnetic moment associated with the 'H or 19F nuclei along the field direction. The nuclei are perturbed from equilibrium by pulsed radio frequency (RF) radiation at the Lannor frequency, which is a characteristic frequency proportional to the magnetic field strength where nuclei resonantly absorb 5 energy. Upon removing the RF, the nuclei induce a transient voltage in a receiver antenna; this transient voltage constitutes the nuclear magnetic resonance (NMR) signal. Spatial information is encoded in both the frequency and/or phase of the NMR signal by selective application of magnetic field gradients that are superimposed onto the large static field. The transient voltages are generally 10 digitized, and then these signals may be processed by, for example, using a computer to yield images. At constant magnetic field strength, the Larmor frequency of 1F is only slightly lower (-6 %) compared to 'H. Thus, it is straightforward to adapt conventional MRI scanners, both hardware and software, to acquire ' 9 F data. The ' 9 F 15 detection may be coupled with different types of magnetic resonance scans, such as MRI, MRS or other techniques. Typically, it will be desirable to obtain a 'H MRI image to compare against the 1 9 F image. In a living organism or other biological tissue, the proton MRI will provide an image of the subject material and allow one' to define the anatomical context of the labeled cells detected in the ' 9 F image. In a 20 preferred embodiment of the disclosure, data is collected for both 1 9 F and 'H during the same session; the subject is not moved during these acquisitions to better ensure that the two data sets are in spatial registration. Normally, 19F and 'H data sets are acquired sequentially, in either order. An RF coil (i.e. antenna) can be constructed that can be electrically tuned from the ' 9 F and 'H Larmor frequency. Tuning 25 between these two frequencies can be performed manually (e.g. via an electro mechanical variable capacitor or inductor), or electrically, via active electronic circuitry. Alternatively, with appropriate modifications to the hardware and/or software of the MRI instrument, both data sets can be acquired simultaneously, for example, to conserve imaging time. Simultaneous acquisition of the ' 9 F and 'H data 30 sets require an RF coil or antenna that can be electrically tuned simultaneously to the 1 9 F and 'H Larmor frequency (i.e., a double-tuned coil). Alternatively the RF coil can be "broadband," with one broadly-tuned electrical resonance that covers both WO 2007/120911 PCT/US2007/009391 46 Larmor frequencies (i.e. ' 9 F and 'H). Other imaging techniques, such as fluorescence detection may be coupled with ' 9 F MRI. This will be particularly desirable where a fluorocarbon imaging reagent has been derivatized with a fluorescent moiety. In other embodiments, the ' 9 F MRI scan may be combined with a PET scan in the same 5 subject or patient by using dual-model radioactve ' 8 F/1 9 F fluorocarbon labeling reagents as described herein. MRI examination may be conducted according to any suitable methodology known in the art. Many different types of MRI pulse sequences, or the set of instructions used by the MRI apparatus to orchestrate data collection, and signal 10 processing techniques (e.g. Fourier transform and projection reconstruction) have been developed over the years for collecting and processing image data (for example, see Magnetic Resonance Imaging, Third Edition, editors D.D. Stark and W.G. Bradley, Mosby, Inc., St. Louis MO 1999). The reagents and methods of this disclosure are not tied to any particular imaging pulse sequence or processing 15 method of the raw NMR signals. For example, MRI methods that can be applied to this disclosure broadly encompasses spin-echo, stimulated-echo. gradient-echo, free induction decay based imaging, and any combination thereof. Fast imaging techniques, where more than one line in k-space or large segments of k-space are acquired from each excited signal, are also highly suitable to acquire the ' 9 F (or 'H) 20 data. Examples of fast imaging techniques include fast spin-echo approaches (e.g. FSE, turbo SE, TSE, RARE, or HASTE), echo-planar imaging (EPI), combined gradient-echo and spin-echo techniques (e.g. GRASE), spiral imaging, and burst imaging. Furthermore, rapid acquisition schemes using reduced k-space sampling known in the art are highly appropriate for 19F imaging (e.g., key-hole imaging, 25 single value decomposition encoding, reduced imaging using generalized series reconstruction, RIGR, and the like). Ideally, in these sampling schemes only the central parts of k-space are acquired where most of the ' 9 F signal is present. Although some edge resolution loss may occur, often only a low resolution ' 9 F image is needed, and the 'H image overlay provides the fine anatomical detail. The 30 development of new and improved pulse sequence and signal processing methods is a continuously evolving field, and persons skilled in the art can devise multiple ways to image the ' 9 F labeled cells in their anatomical context.
WO 2007/120911 PCT/US2007/009391 47 As another example of a nuclear magnetic resonance technique, MRS can be used to detect the presence of fluorocarbon-labeled cells in localized tissues or organs. Normally MRS methods are implemented on a conventional MRI scanner. Often the localized volume of interest (VOI) is defined within a conventional 5 anatomical 'H MRI scan. Subsequently, the magnitude of the 19F NMR signal observed within the VOI is directly related to the number of labeled cells, and/or the mean concentration of PFPE per cell present in the tissue or organ. Methods for isolating a VOI within a much larger subject are well known the art (for example, Magnetic Resonance Imaging, Third Edition, Chapter 9, Editors D.D. Stark and 10 W.G. Bradley, Mosby, Inc., St. Louis MO 1999). Examples include using a localized RF surface coil near the VOI, surface spoiling, surface coil B i-gradient methods, slice-selective Bo-gradient techniques, STEAM, PRESS, image selective in vivo spectroscopy (ISIS), and magnetic resonance spectroscopic imaging (MRSI). The development of new and improved pulse sequence and signal processing 15 methods is continuously evolving for MRS, and persons skilled in the art can devise multiple ways to detect the ' 9 F NMR signals emanating from the fluorocarbon labeled cells in VOIs. In certain embodiments the disclosure provides a method of quantifying the numbers of labeled cells in vivo or in subject materials within an RO. An ROI may 20 include all labeled cells in a subject or labeled cells in specific organs such as the pancreas, specific tissues such as lymph nodes, or any region or of one or more voxels showing detectable MRI/MRS 1 9 F signal. A ROI can be an otherwise undefined area beyond a particular experiment. There are a number of ways that labeled cells may be quantified in the subject materials or in vivo, as described 25 herein. Calibrating the mean "cellular dose" of 1 9 F labeling agent pre-implantation of a particular cell population is often a pre-requisite for quantitative cell determinations in subject materials or the patient. It is anticipated that different cell types have different innate abilities to take up the labeling agents in vitro, and thus 30 the cellular dose of the labeling agent will also vary. Furthermore, different cells of the same type acquired from different sources (e.g., different patients) may have different affinities for the labeling agent. Thus a cellular dose calibration may be WO 2007/120911 PCT/US2007/009391 48 required. This calibration may be used, initially, to modify the labeling protocol (i.e., incubation conditions, duration of time that cells are incubated with labeling fluorocarbon emulsion, concentration of fluorocarbon emulsion in culture medium during labeling, etc.) to achieve a certain range of cellular dose before labeled cells 5 are actually used in a subject to be imaged. Alternatively, one can fix the labeling conditions and protocol and measure the mean value 19F labeled per cell, as is, for subsequent quantification in the subject to be imaged. In certain embodiments the mean number of 1 9 F molecules (F's) per cell of a labeled cell population is measured (i.e., calibrated) in vitro prior to administration of the cells to the subject or patient. 10 In certain embodiments the mean number of 1 9 F molecules (F's) per cell of a labeled cell population is calibrated in a test population of cells of a particular type, not necessarily destined for a patient, but used to calibrate cellular dose of labeling agent as a consequence of a particular labeling protocol or set of conditions; optionally, the value of cellular dose is then used for future labeling and in vivo imaging 15 experiments in the same population type of cells with the same labeling protocol. The cellular dose of labeling agent can be assayed in vitro using a variety of quantitative techniques. For example, one can use a one-dimensional (ID) 1 9 F NMR spectrum obtained from a cell pellet, cell suspension, or cell lysate, of a known number of labeled cells. From this spectrum, one can calculate the integrated area of 20 the ' 9 F spectrum or a portion thereof, originating from the labeling reagent associated with the cells. The integrated area of the 19F spectrum, denoted Seens, is directly proportional to the total amount of ' 9 F in the cell pellet, suspension, or lysate. To measure the absolute number of 1 9 F nuclei, the measured Seens may be normalized to a ' 9 F standard. A ' 9 F standard can be, for example, a solution of a 25 known volume and concentration of a fluoro-chemical, where one can calculate the total number of ' 9 F nuclei in the standard, denoted Fstan. A suitable fluoro-chemical reference ideally has a simple '9F NMR spectrum, preferable with a single narrow resonance (e.g. trifluoroacetic acid or trifluoroethanol) and optionally a 1 9 F chemical shift that is significantly different than the labeling fluorocarbon. The 19F standard 30 can be placed in the same NMR tube as the labeled cell material being measured, in a separate tube, or optionally can be measured in a separate experiment using the same NMR instrument. The integrated area of the spectrum from the 1 9 F standard, WO 2007/120911 PCT/US2007/009391 49 denoted Ssan, can then be measured. Subsequently, the mean number of ' 9 F per labeled cell, denoted Fe, can be calculated, for example using the formula: F = &kF i. where Ncetis is the number of labeled cells contained in the in vitro test sample. An example of this calibration procedure is described herein in the Examples. 5 Quantitative NMR methods for ' 9 F and other nuclei are well know in the art, and those skilled can devise many variations to the cellular dose calibration procedure described above. Besides 1 9 F NMR, there are other quantitative methods that can be used to assay the cellular dose of the labeling reagent. For example, a reagent may be labeled fluorescently, luminescently, optically, or radioactively. 10 In order to extract accurate quantification of labeled cells from the 1 9 F MRI/MRS data sets, additional calibrations and standards may be employed. For example, one can use a calibrated external ' 9 F reference (i.e. phantom) during the actual ' 9 F MRI/MRS scan of the subject material containing labeled cells. The image intensity of the calibrated phantom is used when analyzing the ' 9 F MRI/MRS data 15 set to proved an absolute standard for the number of ' 9 F nuclei when examining the subject material or patient. The calibrated phantom is used to normalize the sensitivity of the particular MRI/MRS system that has been loaded with a particular subject to be imaged. The ' 9 F reference may be, for example, one or more vessels containing a solution of a known concentration of 1 9 F nuclei. In preferred 20 embodiments, the solution contains a dilute concentration of the emulsified fluorocarbon labeling reagent. Optionally, the solution contains non-emulsified fluorocarbon labeling reagent, a gel, or liquid, for example that has been diluted in a suitable solvent. Optionally, the solution can be comprised of another fluoro chemical, ideally with a simple 19F NMR spectrum, preferable with a single narrow 25 NMR resonance (e.g. trifluoroacetic acid (TFA) or trifluoroacetamide (TFM) and other fluorinated acids). In preferred embodiements, the TI and T2 values of the reference solution are similar to those of the labeling reagent. Optionally, the solution can contain perfluorocarbon-labeled cells, or lysates of the same. The non cellular reference has the advantage of longer storage times. Optionally, the solution 30 can take the form of a gel. The vessel containing the solution is preferably sealable, WO 2007/120911 PCT/US2007/009391 50 and can take a variety of geometries; preferred vessel geometries include ellipsoidal, cylindrical, spherical, and parallel piped shapes. One or more vessels containing 19F reference solution can be used during the 19F MRI/MRS of the subject material. If multiple ' 9 F references (i.e. vessels) are used they can contain the same 9F 5 concentration or different concentrations, and in the case of the latter, they ideally contain graded concentrations of fluoro-chemical. The placement of the calibrated 1 9 F reference vessel(s) can be placed preferably externally or alongside, or optionally inside, the imaged subject or patient prior to data acquisition. In preferred embodiments, the reference is imaged using ' 9 F MRI along with the subject in the 10 same image field of view (FOV). Optionally, 1 9 F MRS data is acquired in the reference either sequentially or in parallel with the subject data set. Optionally, data from the reference can be acquired using MRI/MRS acquired in a separate scan. Optionally, the external reference is not scanned along with a subject in every 1F MRI/MRS examination, but rather, values of the reference 1 9 F signal intensity 15 acquired using MRI/MRS is used from a scan of a comparable subject or a simulated-subject. In a given 19F MRI/MRS scan, the calibrated ' 9 F standard may be sampled by one or more voxels. The observable ' 9 F intensity produced by a voxel may be proportional to the concentration of the fluorochemical in the solution (or gel) and the voxel volume. Often in a 19F MRI scan the reference standard is 20 comprised of many voxels. Often one calculates the mean intensity of one, several, or all voxels in the reference standard. Optionally, the mean image intensity is calculated over an ROI defined within the ' 9 F image of the reference standard. Optionally, the physical geometry of the reference standard vessel contributes to defining the observed 19F signal intensity; for example, the volume compartment(s) 25 containing the ' 9 F reference solution is smaller than the voxel volume. In other embodiments, the calibrated external reference relies on a solution with a 'H signal intensity of a known number of detectable 'H; in this case the sensitivity of the ' 9 F signal in the subject material is reference to a 'H calibrated standard. Ideally the solution or gel in the 'H calibrated reference (contained in a vessel as described 30 above) yields a simple 'H NMR spectrum, preferable with a single narrow NMR resonance (e.g., H20, or mixtures of H 2 0-D 2 0). Other than a different nuclei, the use of the 'H standard reference is the same in many other respects as described WO 2007/120911 PCT/US2007/009391 51 above for the ' 9 F reference. In some embodiments, the 'H reference is an internal organ or region of tissue and the data may be raw or normalized. Optionally, the calibrated reference standard contains any other MRI/MRS-active nuclei. In other embodiments, the reference is a standard that is not scanned with the subject, but is 5 calibrated by relevant factors such as the weight of the patient or the size of the body cavity. By computationally manipulating or combining a key set of parameters from the 1 9 F MRI/MRS data set, one can calculate the number of labeled cells present in an ROI as described herein. For example, a key set of parameters may include: (i) 10 the cellular dose of labeling agent (i.e., Fe) measured in vitro; (ii) in vivo ' 9 F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane voxel area (i.e., area of the image pixel); (v) optionally, the MRI/MRS data set from the 1 9 F reference standard; (vi) optionally, the measured Johnson noise of the ' 9 F MRI/MRS data in 15 the subject material; (vii) optionally, the measured signal-to-noise ratio (SNR) of one or more voxels of the ' 9 F MRI/MRS data set in the subject material; (viii) optionally, the measured SNR of one or more voxels of the 19F MRI/MRS data set from the reference standard; (ix) optionally, the ' 9 F NMR relaxation times (TI, T2, and T2*) of the subject material; (x) optionally, the ' 9 F NMR relaxation times (TI, 20 T2, and T2*) of the reference standard (for example, see Magnetic Resonance Imaging, Third Edition, chapter 4, editors D.D. Stark and W.G. Bradley, Mosby, Inc., St. Louis MO 1999). Those skilled in the art can derive other parameters, combinations of the above set, or derivations thereof, particularly from the 1 9 F MRI/MRS dataset, that can be used to quantify the number of labeled cells in situ. In 25 certain embodiments the above set of key parameters can be used to derive quantitative or statistical measures of the accuracy or confidence of the measured number of labeled cells. There are many ways to combine the key parameters (i-x, above), any subsets of these, or any of their combinations or approximations, to estimate the 30 effective number of labeled cells seen by 1 9 F MRI in the subject material, denoted by No. For example, one can use an equation of the form N __F___ 'A , WO 2007/120911 PCT/US2007/009391 52 where: N, = total number of labeled cells in the ROI; [FR] = concentration of 1 9 F in the calibrated ' 9 F reference solution (or gel); v = voxel volume; IR = mean intensity of the calibrated ' 9 F reference taken with the MRI/MRS scan, averaged over one or more voxels; Fc = average ' 9 F cellular dose of the labeling agent measured in vitro; 5 NRoI = number of voxels in the ROI containing labeled cells; 1l(e) = image intensity of the ith voxel in the ROI containing labeled cells; i = unitless index for voxels in the ROI containing labeled cells. There are also many ways to approximate N. from the ' 9 F data set. For example, one could use the expression ~avg N, ~ [ FR ]V - NVRG, IR F 10 where Icav9 is the average intensity of the ROI containing the labeled cells, (i.e. the average intensity of the NRoI voxels). As another example, one could use J"" 1 N, ~- I V, -- [ FR IR F where V_ is the total volume of the ROI containing the labeled cells. As a further example, one could use N C V 'in VR F, where VR is the effective volume of the reference in the 1 9 F MRI/MRS and NR is the 15 number ' 9 F nuclei in VR. Note that in all of the above formulas the various intensities (i.e., IR, Icavg oP)) can be normalized to the image noise, and thus the above formulas can be equivalently expressed in terms of the appropriate SNR values for the particular regions. Thus, there are many ways to estimate the number of labeled cells, No, and many similar forms of these basic expressions can be 20 derived by basic mathematical manipulations, however, all rely on the same basic content contained within the input parameters described by (i-x). Furthermore, quantification of labeled cells in an ROI need not be expressed in terms of absolute numbers or effective cell numbers. Other quantitative indices can be derived that are indicative of the amount of cells in an ROI. For example, one can calculate the ratio 25 Icavg/R, or the ratio of the average SNR values observed in the ROI and the 0 WO 2007/120911 PCT/US2007/009391 53 reference; all of these fall within subsets of the above expressions and/or the parameters. In certain embodiments, the quantity of apparent PFPE-labeled cells is calculated directly from the in vivo MRI data set, the external 1 9 F reference, and the measured Fe, where the calculation is performed on a per-slice basis. 5 It is noted that the above analysis of cell numbers and related indices assume that the 1 9 F NMR relaxation times (i.e., particularly TI and/or T2) of the fluorocarbon label is approximately the same as material in the calibrated 1 9 F reference standard. In the case that the relaxation times are not comparable, one of skill in the art can readily correct for this by employing the known MRI intensity 10 equations of the particular imaging protocol being used, expressed in terms of TI and T2. Optionally, the 19F MRI data set of the subject material can undergo post processing before the actual cell quantification calculation is performed (as described above). For example, post-processing algorithms may include "de 15 noising" the 19E data set. This can be accomplished by, for example, by thresholding the image to cut off low-intensity noise; this involves resealing the image intensity so that low values are set to zero. In magnitude MRI images, random Johnson noise is often apparent and uniformly distributed across the image FOV. It is well know in the art that one can threshold out the low-level image intensity so that regions 20 known to contain no true signal (i.e. devoid of 1 9 F and/or 1H nuclei ) appear to have a null or very near-null intensity. This process can be performed in an ad-hoc fashion (i.e. "manually" or by visual inspection), or by using a computer algorithm. In other embodiments, de-noising of the data set can be achieved by using other algorithms, for example using wavelet analysis or Rician corrections (21), and many 25 methods are known in the art for image de-noising. The following references are incorporated in their entirety herein: Khare, A., et al., INTERNATIONAL JOURNAL OF WAVELETS MULTIRESOLUTION AND INFORMATION PROCESSING, 3 (4): 477-496 DEC 2005; Cruz-Enriquez, H., et al., IMAGE ANALYSIS AND RECOGNITION, 3656: 247-254 2005; Awate, SP., et al., 30 INFORMATION PROCESSING IN MEDICAL IMAGING, PROCEEDINGS, 3565: 677-688 2005; Ganesan, R., et al., IE TRANSACTIONS, 36 (9): 787-806 WO 2007/120911 PCT/US2007/009391 54 SEP 2004; Scheunders, P., IEEE TRANSACTIONS ON IMAGE PROCESSING, 13 (4): 475-483 APR 2004; Ghugre, NR., MAGNETIC RESONANCE IMAGING, 21 (8): 913-921 OCT 2003; Bao, P., et al., IEEE TRANSACTIONS ON MEDICAL IMAGING, 22 (9): 1089-1099 SEP 2003; Wu, ZQ., et al., ELECTRONICS 5 LETTERS, 39 (7): 603-605 APR 3 2003; LaConte, SM., et al., MAGNETIC RESONANCE IN MEDICINE, 44 (5): 746-757 NOV 2000; Laine, AF., ANNUAL REVIEW OF BIOMEDICAL ENGINEERING, 2: 511-550 2000; Zaroubi, S., et al., MAGNETIC RESONANCE IMAGING, 18 (1): 59-68 JAN 2000; Nowak, RD., IEEE TRANSACTIONS ON IMAGE PROCESSING, 8 (10): 1408-1419 OCT 10 1999; and Healy, DM., et al., ANNALS OF BIOMEDICAL ENGINEERING, 23 (5): 637-665 SEP-OCT 1995. Other types of post-processing algorithms are know in the art that can be applied to the ' 9 F MRI data set before or after quantification, such as zero-filling (A Handbook of Nuclear Magnetic Resonance, 2 "d Edition, Ray Freeman, Addison 15 Wesley Longman Press 1997) and various image interpolation, de-noising, and image smoothing algorithms (for example, see The Image Processing Handbook, 3 rd Edition, John C. Russ, CRC Press/IEEE Press). In certain embodiments the above set of key parameters (i-x) can be used to derive quantitative or statistical measures of the accuracy or confidence of the 20 measured number of labeled cells or related indices. 19F MRI/MRS data sets are often subject to SNR limitations within ROI, and thus it is often useful to calculate a metric of the confidence or accuracy of the measurement. Many methods are known in the art for the statistical analysis of MRI and other biomedical-type images. The claimed embodiment is understood to encompass these known methods. 25 5. Computer methods Methods for quantifying labeled cells will typically be conducted with the aid of a computer, which may operate software designed for the purpose of such quantification. Such software may be a stand-alone program or it may be WO 2007/120911 PCT/US2007/009391 55 incorporated into other software, such as MRI image processing software. Figure 16 shows a functional block diagram of general purpose computer system 200 for performing the functions of the computer according to an illustrative embodiment of the disclosure. The exemplary computer system 200 includes a central processing 5 unit (CPU) 202, a memory 204, and an interconnect bus 206. The CPU 202 may include a single microprocessor or a plurality of microprocessors for configuring computer system 200 as a multi-processor system. The memory 204 illustratively includes a main memory and a read only memory. The computer 200 also includes the mass storage device 208 having, for example, various disk drives, tape drives, 10 etc. The main memory 204 also includes dynamic random access memory (DRAM) and high-speed cache memory. In operation, the main memory 204 stores at least portions of instructions and data for execution by the CPU 202. The mass storage 208 may include one or more magnetic disk or tape drives or optical disk drives, for storing data and instructions for use by the CPU 202. At 15 least one component of the mass storage system 208, preferably in the form of a disk drive or tape drive, stores the database used for processing the cell quantification of the disclosure. The mass storage system 208 may also include one or more drives for various portable media, such as a floppy disk, a compact disc read only memory (CD-ROM), or an integrated circuit non-volatile memory adapter (i.e. PC-MCIA 20 adapter) to input and output data and code to and from the computer system 200. The computer system 200 may also include one or more input/output interfaces for communications, shown by way of example, as interface 210 for data communications via the network 212. The data interface 210 may be a modem, an Ethernet card or any other suitable data communications device. To provide the 25 functions of a computer, the data interface 210 may provide a relatively high-speed link to a network 212, such as an intranet, internet, or the Internet, either directly or through another external interface. The communication link to the network 212 may be, for example, optical, wired, or wireless (e.g., via satellite or cellular network). Alternatively, the computer system 200 may include a mainframe or other type of 30 host computer system capable of Web-based communications via the network 212. The computer system 200 also includes suitable input/output ports or uses the interconnect bus 206 for interconnection with a local display 216 and keyboard WO 2007/120911 PCT/US2007/009391 56 214 or the like serving as a local user interface for programming and/or data retrieval purposes. Alternatively, server operations personnel may interact with the system 200 for controlling and/or programming the system from remote terminal devices via the network 212. 5 The computer system 200 may run a variety of application programs and stores associated data in a database of mass storage system 208. One or more such applications may enable the receipt and delivery of messages to enable operation as a server, for implementing server functions relating to quantification. The components contained in the computer system 200 are those typically 10 found in general purpose computer systems used as servers, workstations, personal computers, network terminals, and the like. In fact, these components are intended to represent a broad category of such computer components that are well known in the art. Certain aspects of the disclosure may relate to the software elements, such as the executable code and database for the server functions of the quantification 15 system. The disclosure will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present application, and are not intended to limit the disclosure. 20 EXAMPLES Data presented in W02005072780 demonstrated that immune cells and other cell types cells could readily be labeled with a fluorocarbon imaging reagent ex vivo, and that labeled cells could be detected in vivo. In this section, data demonstrating the further feasibility of the disclosed methods is presented, including data 25 demonstrating the in vivo quantification of labeled cells. The overall scheme is summarized in Figure 1. The exemplary embodiment of the disclosure uses fluorine based imaging reagents to label cultured cells. Labeled cells are introduced into a living subject and tracked in vivo using 19F MRI or MRS, as shown in Figure 2 1 9 F MRI images are overlaid with 'H MRI images to establish the anatomical location of 30 the labeled cells as shown in Figures 2, 9A and 13. In the examples, quantification WO 2007/120911 PCT/US2007/009391 57 of labeled cells'in an ROI in the subject is measured using the ' 9 F intensity of the ROI and a calibrated external 1 9 F reference. 1. Emulsion preparation 5 A label formulation was prepared, consisting of a 1:1 molar ratio of the PFPE (Exfluor, Round Rock, TX) molecule shown in Figure 3c with Pluronic L-35 (Sigma-Aldrich, St. Lois, MO). The PFPE and water were autoclaved, and the Pluronic L-35 was 0.22 pm filtered to ensure sterility. The mix was emulsified by probe sonication on ice. Light scattering using standard means was performed on the 10 emulsified product to confirm particle size distribution as shown in Figure 3d. Dynamic light scattering was done using a Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) instrument. The nanoparticles have an average diameter of 103 4 nm. 15 2. Cell labeling T cells were extracted from the mouse spleen, and single cell suspensions of splenocytes were sorted using a MACS pan T-cell isolation kit (Miltenyi Biotec, Auburn CA). (See Example 6 for additional details.) T cells were activated before labeling by incubating them in plates coated with anti-TCR, anti-CD-28, and IL-2 20 for 3 days. The cells were maintained in RPMI with 10% fetal bovine serum (FBS), 100 ptg/ml each of streptomycin and penicillin, and supplemented with 10 ptg/ml IL 2 and I pl/ml of 2-mercaptoethanol. Cells were then harvested and resuspended in fresh medium at 2 million/ml. Label was prepared by mixing 2 pl of the PFPE emulsion and 8 pl of FuGene 6 (Roche, Inc., Indianapolis IN) in 300 il FBS-free 25 media for 20 min before adding to the cell suspension at 2 R1 label/ml cells for 3 hrs. Cells were washed in PBS twice and resuspended in 300 p. HBSS before administration to the subject. Between four and eight million cells were used for each experiment (n=6). 1 9 F NMR, shown in Figure 3a, was used to confirm cell labeling and for 30 quantification of the intracellular dose (i.e., Fe or "cellular dose") of the labeling reagent. Figure 3a shows a 1 9 F NMR spectrum of activated, labeled T cells. The spectrum of the linear PFPE molecule has two peaks, a major CF 2 peak at -92 ppm and a minor peak at -79 ppm from the CF 2 end groups (Fig. 3c). The ratio of the WO 2007/120911 PCT/US2007/009391 58 spectral weight of these peaks is 10:1, and generally the minor peak is below MRI detectability in vivo. The third peak, at -76 ppm, is from the TFA reference in a sealed capillary. We calculated the mean 19F content per cell (Fe) to be 2.2x10" fluorine atoms post-labeling. Confocal microscopy of the labeled cells confirmed 5 that the PFPE label distribution is intracellular and also on the cell surface (Fig. 3b). Besides FuGene, many other transfection agents can be used to boost the PFPE labeling of many cell types. Figure 4b shows that T cells can also be labeled with Lipofectamine (Invitrogen, Inc., Carlsbad, CA) and DOTAP (Roche). In other examples shown in Figure-4a, DC labeling can be boosted with the aid of the small 10 cationic protein, protamine sulfate, and the labeling results give the same order of magnitude as what is achievable with Lipofectamine (Figure 4a). In the examples shown in Figure 4, the 19F content was assayed using the integrated ' 9 F NMR spectrum of the labeled cell pellet, where values were normalized to cell number and a TFA reference located next to the cell pellet. 15 As alternative to the use of transfection agents, one can use cell electroporation to boost PFPE labeling. Figure 5a shows a 1 NMR spectrum of a pelleted DCs that have been electroporated with PFPE emulsion particles while in culture. By varying the electroporation parameters, such as the electroporation voltage, one can systematically vary and optimize the amount of label internalized 20 into the cells, as shown in Figure 5b. As above, the 19F content was assayed using the integrated 1 9 F NMR spectrum of the labeled cell pellet, where values were normalized to cell number and a TFA reference located next to the cell pellet. In the electroporation experiments a commerecially available apparatus was used (ECM 830, BMX, Inc., Holliston, MA). Before electroporation DCs were resuspend in 25 HBSS so that each sample had about 1-1.6 million cells in a 700 pl in the-cuvette. The PFPE emulsion (2 pl/ml) was added directly into the cuvette. For the data shown in Figure 5b, a single 20 Ls electroporation pulse was used. One minute after the pulse, 1 ml of culture media was added, and the samples were kept on ice for -10 minutes. The cells were then washed twice in PBS to remove excess (i.e,, 30 unincorporated) PFPE.
WO 2007/120911 PCT/US2007/009391 59 3. "F Labeling does not affect cell behavior T cell labeling was optimized for maximal uptake and minimal cytotoxicity. Label uptake was measured through ' 9 F NMR and cytotoxicity through standard assays, such as trypan blue exclusion and MTT assays. To confirm viability and 5 phenotype of labeled T cells, we performed several in vitro assays. Labeled cell viability, assayed using trypan blue immediately after labeling, showed 94+3.7% viability relative to untreated controls, where the error bar is the standard deviation for n=6 wells; at 48 hours post-labeling, the cells displayed 95+6% viability (n=3). The MTT assay (ATCC, Manassas, VA) was carried out on T cell aliquots taken at 2 10 and 4 hours post-labeling. Data were normalized to untreated controls. Labeled cells showed minimal decrease in the MTT relative to controls, as shown in Figure 6. Thus, these data suggest that the label process causes no overt toxicity. In addition, the lack of cytoxicity was confirmed by the trypan exclusion assay and direct cell counts. 15 To confirm that the labeling process itself does not activate T cells, we studied expression of the cell surface markers CD62L and CD4 on naive BDC2.5 T cells after labeling. CD62L, a lectin-binding protein that aids in lymphocyte rolling, is expressed at high levels only on naive T cells. We found minimal downregulation in the expression of CD62L in labeled cells compared to unlabeled cells (Fig. 7a), 20 indicating that labeling does not activate naive T cells. CD4, a co-receptor that interacts with the MHC II molecule, is expressed on both naive and activated T cells. The level of CD4 expression was reduced immediately after labeling using the transfection agent, but recovered within 24 hours (Fig. 7b). To better understand the origin of this transient downregulation, T cells were labeled via electroporation, 25 without transfection agent. There was no reduction in CD4 expression immediately after labeling using electroporation (Fig. 7c), indicating that this effect is likely an artifact from transfection agent usage. In vitro retention studies showed that the label is retained for at least 24 hours. Intracellular localization of the label was confirmed by electron microscopy. 30 Correct in vivo cell homing and function of labeled cells was confirmed using fluorescence microscopy (Figure 8). To test this, we investigated T cell infiltration into the pancreas in a Type I diabetes model. For all in vivo experiments WO 2007/120911 PCT/US2007/009391 60 we used an established adoptive transfer method that has been shown to result in reproducible diabetes induction (22,23). The BDC2.5 T cells (-4x106) were purified, activated in vitro, PFPE labeled, and injected i.p. into a recipient NOD SCID mouse (Jackson Labs, Bar Harbor ME). All T cells in the NOD BDC-2.5 5 transgenic only recognize a peptide derived from a specific B cell granule protein. Adoptive transfer of NOD BDC 2.5 T cells is known to cause diabetes in NOD SCID mice. All mice were 8-10 week old, and each mouse received -5 million labeled cells. Control mice received an equivalent amount of label in buffer. All NOD SCID mice received 200 mg/kg of cyclophosphamide (Sigma Aldrich) in PBS 10 i.p. 24 hrs before cell transfer. Figure 8 confirms that the PFPE-labeled cells are able to home to the pancreas, showing that the labeling process does not interfere with cell function in vivo. The injected cells were only visible in or around islets and blood vessels, as expected. This suggests specific homing to the islets, rather than merely 15 accumulation of cells in the pancreas. These micrographs also show strong CD4+ immuno-staining, implying strong CD4 expression levels. All detected T cells in the pancreas are those that were labeled and transferred, since NOD SCID mice lack endogenous lymphocytes. 20 4. In vivo cell tracking In vivo MRI experiments were used to confirm that labeled cells can be detected in the appropriate organs (e.g., pancreas). Purified T cells from transgenic NOD BDC 2.5 mice were activated and labeled in vitro, as described above, and transferred i.p. into host NOD SCID mice (Jackson Labs, Bar Harbor Maine). All 25 mice were 8-10 week old, and each mouse received 3-8 million labeled cells. Control mice received an equivalent amount of emulsified PFPE in buffer without cells. All NOD SCID mice received 200 mg/kg of cyclophosphamide (CY) i.p. 24 hours before cell transfer. Animals were imaged 48 hours after cell transfer. Prior to MRI, mice were 30 anesthetized, intubated, and connected to a mechanical respirator. A capillary tube containing a 1 9 F reference, comprised of the PFPE emulsion containing 1018 fluorine atoms per ml of PBS, was placed next to the animal in the image field of view. MRI WO 2007/120911 PCT/US2007/009391 61 was carried out using an 11.7 T, 89 mm vertical-bore micro-imaging system (Bruker Instruments, Inc., Billerica, MA). 1 9 F images were acquired using a RARE sequence with TR/TE = 1000/6.4 ms with a RARE factor of 8, a matrix of 164x32 image points, and a slice thickness of 2 mm. 'H imaging was performed immediately 5 afterwards using a 2DFT spin-echo sequence, with TR/TE= 1200/22 ins, 512x256 image points, and the same geometrical coordinates as the ' 9 F. All in vivo imaging was respiratory-gated, and animal temperature was maintained at 37 "C. A representative t 9 F/'H composite image is shown in Fig. 9a. The anatomical
T
2 -weighted 'H image (grayscale) that serves as an underlay was acquired with the 10 same slice geometry and in the same imaging session as the 1 9 F. The 19F images through the torso show localized signal in a region consistent with the pancreas (pseudo-color, Fig. 9a). No signal was detected in any other regions, including the liver and spleen, indicating that the cells are not being taken up by these organs in significant numbers. Moreover, cells that remained in circulation or that were 15 localized at low concentrations in other organs or tissues are not detected. The complete lack of signal in any other region shows specific trafficking to the pancreas, which is the expected immunological response in vivo. To confirm that the detected signal was due to specific T cell homing, we carried out two control in vivo MRI experiments in the NOD model. These 20 employed i.p. injections of either cell-free PFPE nanoparticles or non-specific, labeled T cells. Imaging results after 48 hours (Fig. 9b) show 1 9 F accumulation from cell-free PFPE in regions in or near the bladder but not the pancreas. The second control employed purified non-specific CD4-T cells from MHC-mismatched BALB/c mice. Since T cells recognize antigen in the context of the MHC, BALB/c 25 T cells are not expected to carry out specific homing in NOD mice. Fig. 9c shows that after 48 hours no 1F was detected in or around the pancreas. 5. Quantification through in vivo MRI Using the in vivo 1F MRI data we applied an algorithm (See Example 6) to 30 quantify the effective number of transferred cells within regions of interest. Fig. 9d shows a summary of the cell quantification results in pancreata from n=4 animals. The number of apparent T cells detected ranged from approximately 1.5-3.4% of the WO 2007/120911 PCT/US2007/009391 62 total transferred cells (Fig. 9d). The mean number of cells detected for the cohort was 2.2±0.9% of the total transferred cells, where the uncertainty is the standard deviation (n=4). The average cell density in vivo was -28,000 cells/voxel in the pancreas. 5 We independently validated the quantity of labeled cells homing to the pancreas via high-resolution ' 9 F NMR spectroscopy in excised organs (Fig. 10). The mouse was sacrificed after the MRI scan, and we harvested and fixed the pancreas and other organs. Figure I0a shows a ' 9 F NMR spectrum from an intact, excised pancreas. The area under the ' 9 F NMR peak of the pancreas, measured with respect 10 to a TFA reference sample in the same NMR tube, gives the total ' 9 F content in the organ. In the pancreata, the mean number of cells detected for the cohort using NMR was 2.9±0.3% of the total transferred cells, where the uncertainty is the standard deviation for n=4. Thus, the mean cell numbers obtained by NMR in the excised organs is consistent with the values obtained using in vivo 19F MRI. The excised 15 spleens showed minimal ' 9 F NMR signal (Fig. 10b), as is seen in the MRI data. As an additional verification of the accuracy of the MRI cell quantification methods, we imaged a phantom containing a range of known densities of fixed, labeled T cells suspended in agarose. Fig. 1 la displays a composite "9F/'H image of the phantom and the ' 9 F image alone; this image was acquired with the same 20 parameters that were used for the in vivo data (Fig. 9a). The 'ghost' seen adjacent capillary A is a CF 2 endgroup chemical shift artifact from the highly concentrated reference capillary, R. We calculated the number of apparent cells per voxel directly from the ' 9 F MR images using the same methods that were used for the in vivo data. The measured results are 120, 80, 43, 18 and 5.7 (x10 ) cells/voxel, for capillaries 25 A, B, C, D and E respectively (Fig. 11 b). The Pearson correlation coefficient was 0.98, when compared to the actual cell numbers per voxel. Overall, the phantom experiment demonstrated reasonable accuracy of the quantitative methods, with a minimum cell detection limit of approximately 7,500 cells/voxel.
WO 2007/120911 PCT/US2007/009391 63 6. Methods for Examples 1-5 Label synthesis and characterization PFPE emulsions were prepared using a 1:1 molar ratio of autoclaved perfluoro-polyethelene glycol (molecular weight -1500, Exfluor, Round Rock, 5 Texas) and sterile filtered Pluronic L35 (Sigma-Aldrich, St. Louis, Missouri). Emulsification was by probe sonication using a Sonifier Cell Disruptor (Misonix Inc., Farmingdale, New York). The average emulsion particle diameter was determined to be 103±4 nm by dynamic light scattering using a Malvern Zetasizer Nano ZS instrument (Malvern Instruments, Worcestershire, United Kingdom). 10 Fluorescent PFPE emulsion particles were prepared by mixing 2 tl PFPE emulsion, 1 pg dialkylcarbocyanine dye (DiI, Molecular Probes-Invitrogen, Carlsbad, California) dissolved in dimethyl sulfoxide (1 il), 8 pl FuGENE 6 (Invitrogen), and 100 pl Roswell Park Memorial Institute (RPMI) media. 15 T cell purification, activation and labeling T cells from the BDC2.5 TCR transgenic mouse were purified from single cell suspensions of splenocytes using a magnetic cells sorting (MACS) pan T-cell isolation kit (Miltenyi Biotec, Auburn, California). Cell were grown in RPMI with 10% fetal bovine serum (FBS; both from Gibco, Carlsbad, California), 100 pg/ml 20 each of streptomycin and penicillin, and 1 pl/ml of 2-mercaptoethanol. Cells were activated in vitro by a three day incubation on plates coated with anti-TCR antibody in the presence of 1 jig/ml anti-CD28 and 10 U/ml IL-2. Cells were then harvested and resuspended in fresh medium at 2x 106 /ml. The PFPE- emulsion (2 pl) was pre mixed with 8 pA of FuGENE 6 (Roche, Indianapolis, Indiana) transfection agent in 25 300 [d FBS-free media for 20 minutes; this mix was added to the cell suspension at 2 pl /ml and incubated for 3.5 hours. Cells were washed in phosphate buffered saline (PBS) twice and resuspended in 300 pl Hank's balanced salt solution (HBSS) prior to inoculation. Alternatively, electroporation cell labeling was carried out on aliquots of 5x10 6 T cells in HBSS. A unidirectional 80 mV pulse of 20 ms length 30 was delivered via a BTX 830 electroporator (Harvard Apparatus, Holliston, Massachusetts). Cells were then incubated on ice for 10 min before the addition of media and a further incubation of 4 h at 37 "C.
WO 2007/120911 PCT/US2007/009391 64 Cellular toxicity, proliferation and phenotype Cellular viability was measured using the methyl thiazole tetrazolium (MTT) assay (ATCC, Manassas, Virginia) according to the manufacturer's instructions. 5 Cell aliquots were assayed at two, four and 48 hours after labeling. Cellular toxicity of labeled cells was also assessed using a trypan blue exclusion assay; aliquots of cells were mixed with trypan blue and then counted in a hemocytometer. For the fluorescence activated cell sorting (FACS) analyses, cells were stained using either fluorescein isothiocyanate (FITC) or phycoerythrin (PE) conjugated antibodies 10 against CD4 and CD62L (PharMingen, San Diego, California). The expression levels of these markers were determined by flow cytometry on a LSRII FACS instrument (Becton Dickinson, Mountain View, California). Murine diabetes model 15 Experiments were carried out in accordance with the guidelines provided by the Carnegie Mellon Institutional Animal Care and Use Committee (IACUC) and the National Institute of Health Guide for the Care and Use of Laboratory Animals. NOD SCID and BALB/c mice were obtained from Jackson Laboratories, and NOD BDC2.5 mice were bred in house. All mice were housed in the animal facilities at 20 . the University of Pittsburgh or at the Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon University. For the adoptive transfer experiments, purified T cells from the spleens of NOD BDC2.5 mice were activated in vitro, labeled, and transferred intraperitoneally (i.p.) into host NOD SCID mice. Recipient mice were pre-treated i.p. with 200 mg/kg of cyclophosphamide (Sigma-Aldrich) in 25 PBS 24 hours before cell transfer (20). All mice were 8-10 weeks old, and each mouse received 2-6x 106 labeled cells i.p. In vivo control experiments were carried out in exactly the same manner, except mice received either cell-free PFPE in HBSS at a ' 9 F dose equivalent to ~1x107 labeled T cells, or received labeled, activated T cells from MHC 30 mismatched BALB/c mice in place of the BDC2.5 T cells.
WO 2007/120911 PCT/US2007/009391 65 Optical microscopy In vitro activated T cells were incubated with the fluorescent emulsion preparation (described above) and washed twice. T cells were incubated on poly-L lysine coated glass coverslips for 30 min and then fixed in 1% paraformaldehyde 5 (PFA). The fixed cells were mounted in VectaShield (Vector Labs, Burlingame, California) mounting medium with a 10 pg/ml TOTO-3 nuclear stain (Molecular Probes-Invitrogen) after RNAse treatment. The slides were then imaged using a Leica TCS SP2 spectral confocal microscope (Leica Microscopes, Inc., Exton, Pennsylvania). 10 Histological sections were also prepared of the pancreas from NOD SCID mice that had received PFPE labeled NOD BDC2.5 T cells. The mouse was perfused with 2% paraformaldehyde (PFA) 48 hours after cell transfer, and its pancreas was excised and immersed in 2% PFA. Frozen sections (6 tm) were mounted on glass slides, stained, and viewed in an Olympus BX51 microscope (Olympus America, 15 Inc., Center Valley, Pennsylvania). Cell nuclei were stained using 4'-6-Diamidino-2 phenylindole (DAPI), and actin was stained with phalloidin. T cells were immuno stained using rat anti-mouse CD4 primary (Pharmingen-BD Biosciences, San Jose, California) and goat anti-rat Cy3 secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pennsylvania). Insulin was stained using an anti 20 insulin rabbit polyclonal (Santa Cruz Biotechnology, Inc., Santa Cruz, California) and goat anti-rabbit Cy5 secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.). NMR 25 All ' 9 F NMR measurements were made at 470 MHz using a Bruker DRX500 spectrometer (Bruker BioSpin, Inc. Billerica, Massachusetts). The mean intracellular 1 9 F dose per cell, Fe, was measured by pelleting 1x106 labeled cells in an NMR tube. The NMR tube also contained a small sealed capillary containing a 5 p of 5% v/v trifluoroacetic acid (TFA), providing a calibrated quantity of 1 9 F spins. The Fe was 30 calculated from the ratio of the integrated areas of the PFPE and the TFA spectra. For whole organ NMR, mice were sacrificed immediately after MRI, and the organs were harvested and fixed with 4% PFA for 48 hours. The fixed organs were placed WO 2007/120911 PCT/US2007/009391 66 in NMR tubes that also contained a sealed capillary containing the TFA 19F reference solution. All ' 9 F spectra, except where noted, were acquired using a recycle delay of 8 s, a 12 ps pulse width, a spectral width of 20 kHz, 256 averages, 2048 acquisition points, and a 90* flip angle. 5 MRI Before imaging, mice were anesthetized with a ketamine/xylazine cocktail and an IP catheter was secured with sutures and connected to a syringe pump to infuse additional cocktail into the mice for the duration of the experiment (2-3 10 hours). A maximum total dose of approximately 0.33 mg ketamine and 0.02 mg xylazine was delivered via an incremental step-down dose protocol. During the scan the mouse was intubated and connected to a mechanical ventilator (Harvard Apparatus Inc., Hilliston, Massachusetts) delivering a 2:1 0 2 /N0 2 . Mice were positioned in a cradle and imaged using an 11.7 T, 89 mm vertical-bore micro 15 imaging system (Bruker). A volume birdcage-type resonator was used that could be tuned to either 470 MHz for ' 9 F or 500 MHz for 'H. The mouse temperature was maintained at 35-37*C using a water-filled jacket surrounding the animal cradle that was connected to a regulated closed-cycle water bath. A sealed tube containing dilute PFPE emulsion was placed by the torso in the image field of view and served 20 as a calibrated external ' 9 F reference. '9F images were acquired-using a rapid acquisition with relaxation enhanced (RARE) sequence with a RARE factor equal to eight, TR/TE=l 000/6.4 ms, 64x32 image points, and a 50 kHz bandwidth. 'H images were acquired using a 2DFT spin-echo sequence with TR/TE=1200/22 ms and 512x256 image points. Eight contiguous, 2 mm thick slices through the torso 25 were acquired for both 1 9 F and 'H with exactly the same coordinates. The field of view was 5x2.8 cm for all acquisitions. All MRI excitations were respiratory-gated. To validate the MRI cell quantification method, we constructed a phantom containing 5 mm capillaries with different densities of labeled T cells suspended in 2% agarose in PBS. The cell densities used were 87.0, 43.5, 21.9, 10.8, and 5.4 30 cells/nI, which correspond to 12, 6, 3, 1.5, and 0.75 (x10 4 ) cells/voxel, respectively. A 1 9 F reference capillary of dilute emulsion was also placed in the phantom, as is used for the in vivo imaging. All capillaries were embedded in agarose, and imaging WO 2007/120911 PCT/US2007/009391 67 was performed at 37 0 C using the same birdcage resonator and pulse sequence parameters that were used for the in vivo imaging. Cell quantification using MRI 5 The quantity of apparent PFPE-labeled cells was calculated directly from the in vivo MRI data set, the external 1 9 F reference, and the measured F,. The calculation was performed on a per-slice basis. The real-valued noise magnitude, N, of the ' 9 F image was determined by calculating the standard deviation of voxel . values near the periphery of the image. The N can be calculated equivalently from 10 either the real or imaginary component. Next, the magnitude values were calculated for each voxel and then corrected to compensate for the resulting Rician-distributed noise that is observed in low signal-to-noise ratio images (21). Our Rician correction reset the magnitude value, m, to a lower value, n', such that the expected value of the magnitude of (m'+ 0 i) with noise N added to each component of m' is 15 m = E(|(m'+nI) + n2 i 1), where E denotes expected value, and n, and n2 are normally distributed random variables with zero mean and standard deviation N. The m can be estimated statistically for a given m'by finding the mean value of m for a set of random values of n 1 and n2. Random pairs of ny and n2 (1,000,000 trials) were drawn for each estimate of m. To avoid this calculation for each pixel value, m was 20 estimated for m' = 0, 0. IN, 0.2N, ... 8N. The m' is monotonic in m, thus additional m values were calculated by interpolating the m' results using the Matlab function interpl(). Above 8Nno adjustment was made because the Rician distribution is approxiniately Gaussian and the correction was insignificant. Next, the average magnitude signal value, R, was calculated in an ROI containing the ' 9 F reference. 25 The R was calculated by interactively choosing a box containing the reference and automatically identifying voxels within it with magnitude >2.5N, thereby setting a confidence factor of >99% that the voxels scored contain actual ' 9 F signal. This automatically calculated ROI was then dilated by one-half voxel in-plane to capture any nearby signal and account for partial volume effects. From this analysis we also 30 calculated a parameter, r, which is the amount of 1 9 F per voxel in the reference. Next, the total signal in the pancreas, P, was calculated. An ROI was defined by interactively choosing a box containing the pancreas, and voxels with signal >2.5N WO 2007/120911 PCT/US2007/009391 68 were automatically identified in the magnitude images. Again, the identified region's periphery was dilated by 1/2 voxel. The P was then calculated by summing the adjusted magnitude-valued signal from all of the identified voxels. The number of apparent cells contained in the pancreas, C, was calculated using the relationship 5 C=(Pr)/(RFe). The uncertainty in C was estimated by using the equation a(P)r/(RFe), where a(P)=N2n , i.e., the standard deviation of P, and n is the number of voxels identified as having signal. This cell quantification algorithm was also tested on the calibrated phantom containing capillaries with different known densities of labeled T cells suspended in agarose. 10 7. Imaging and quantifying T cells at the site of acute inflammation As an additional example of the utility of the fluorocarbon-based cell labeling and imaging methods, experiments in an acute inflammation model are described. We demonstrate the utility of a dual 1 9 F MRI-fluorescent cell PFPE label 15 in a murine model of localized inflammation. We show that activated T cells can be efficiently labeled with PFPE nanoparticles ex vivo, enabling the selective visualization of homing and quantitation of inflammatory loci in vivo via longitudinal MRI, as well as through optical imaging methods. This provides a convenient model for the study of T cell kinetics. We tracked the migration of 20 antigen-specific T cells in vivo for up to 21 days. Cell number quantification was carried out at five time points directly from the in vivo image data sets. We found that approximately 30 % of transferred cells reach the draining lymph node at 48 hours post-transfer. A fluorescent dye covalently bound to the ' 9 F PFPE label allowed for in vivo optical imaging, as well as recovery and characterization of 25 labeled T cells, through histology and FACS. Taken together, our data demonstrate that this novel dual-mode agent allows for the non-invasive tracking and quantification of cell migration, at least up to 3 weeks after cell transfer. The localized inflammation model described here can be used to study immunological and inflammatory aspects of multiple disease states, such as organ rejection, cancer 30 therapy and autoimmune diseases. This example animal model and the PFPE imaging platform can also be used to quantitatively evaluate the efficacy of small WO 2007/120911 PCT/US2007/009391 69 molecule drugs, recombinant proteins or any other biological or cell-based'therapy that is designed to modulate or attenuate the inflammatory response. Dual-mode PFPE nanoparticles (i.e., MRI and fluorescently active) were prepared using a 1:1 molar ratio of perfluoro-polyethelene glycol (molecular weight 5 -1500, Exfluor, Round Rock, Texas) and .sterile filtered Pluronic L35 (Sigma Aldrich, St. Louis, Missouri). A fraction of the neat PFPE molecule's endgroups were covalently bound to a bright Alexa 647 fluorescent dye (Molecular Probes). Emulsification in water was performed by probe sonication using a Sonifier Cell Disruptor (Misonix Inc., Farmingdale, New York). The average emulsion particle 10 diameter was determined to be 122:17 nm, measured by dynamic light scattering using a Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, United Kingdom). T cells from a DO10. 11 ovalbumin-transgenic mouse were purified from single cell suspensions of splenocytes using a MACS pan T-cell isolation kit (Miltenyi Biotec, Auburn CA). Cells were grown in RPMI with 10% fetal bovine 15 serum, 100 ptg/ml each of streptomycin and penicillin, and I pl/ml of 2mercaptoethanol (Gibco-Invitrogen, Carlsbad, California). Cells were activated in vitro by a three day incubation on plates coated with anti-TCR mAb in the presence of I pg/mi anti-CD28 and 10 U/ml IL-2. Cells were then harvested and resuspended in HBSS at 2 million/ml, with 1 pl/ml of 2-mercaptoethanol. Dilute amounts of the 20 PFPE label were added to the media, and the cells were incubated on ice for 10 min before addition of RPMI with 10% FBS and a further incubation of I h at 37 *C. Cells were washed in phosphate buffered saline (PBS) twice and resuspended in 300 pl Hank's balanced salt solution (HBSS) prior to inoculation. 1 9 F NMR was carried out on representative cell pellets that were labeled as described above. Spectra were 25 acquired using a Bruker Avance 500 MHz NMR spectrometer, where chemical shifts were referenced to TFA, as describe above. The parameter Fe was calculated by pelleting a known number of labeled cells in a capillary tube alongside another tube containing a known concentration of TFA. Approximately 10 million cells were used for each in vivo experiment. Labeled T cells were injected intraperitoneally into 30 female Balb/c (Jackson Labs) MHC-compatible mice (Day 0). These mice simultaneously received 20 pg chicken ovalbumin (Sigma) in PBS, emulsified in IFA, subcutaneously in the quadriceps, and sterile PBS was injected on the WO 2007/120911 PCT/US2007/009391 70 contralateral leg as a negative control. MRI was carried out on anesthetized mice using an 11.7 T, 89 mm vertical-bore micro-imaging system (Bruker, Billerica MA). An external reference capillary of PFPE emulsion diluted in PBS, containing 109' fluorine atoms per ml, was place next to the animal during the imaging sessions. The 5 ' 9 F images were acquired with a RARE sequence with TR/TE=1000/6.4 ms using a RARE-factor of 8 and a matrix of 64 x 32. The 'H imaging was performed using a 2DFT spin-echo sequence with TR/TE=1200/22 ms and a matrix of 512x256. Eight contiguous 2 mm slices and the same slice coordinates were used for both 'H and 1 9 F. All in vivo imaging was respiratory-gated, and the temperature was regulated at 10 37 *C. In vivo optical images were acquired on a Photometrics (Tucson, AR) C258 cooled CCD camera equipped with a custom filter holder and lens adapter (Bioptechs, Butler, PA). Animals were illuminated using four 250 W quartz-halogen illuminators (Cuda Products, Jacksonville, FL). Excitation filters were 530/50 nm, and emission filters were 630/30 nm. Mice were shaved before the imaging to 15 reduce background caused by fur. The mice were sacrificed after imaging, and the lymph nodes extracted for histology. Figure 12 shows an overall schematic of the model used in this study. In vitro activated, ovalbumin-specific T cells were labeled and injected into a MHC matched host mouse, that also received a s.c. injection of antigen emulsified in IFA. 20 Sterile PBS was injected in the other flank as a negative control. Figures 13-15 show exemplary results from these experiments. The in vivo MRI results (Fig. 13) demonstrate specific T cell homing to the lymph node draining antigen. No T cells are visible in the control lymph node. '9F was also detected in the mesenteric regions, especially at the earlier time points. With aid of the external 1 9 F reference 25 capillary, we quantified the number of apparent cells present in the lymph node (Fig. 14) using the methods described above. In vivo optical imaging (Fig. 15a) demonstrates that the dual-mode PFPE nanoparticles in the labeled cells can be imaged in live mice in superficial regions, including mesentery and superficial lymph nodes. The inguinal lymph nodes can overlap with the intestinal loops; to 30 prevent ambiguity in localization, the lymph nodes were excised and imaged separately (Fig. 15b). This panel shows fluorescence only in the draining inguinal WO 2007/120911 PCT/US2007/009391 71 node on the side of the Ova/IFA injection, while the control node had no fluorescence and was also smaller in size. INCORPORATION BY REFERENCE 5 All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control. 10 1. Miyazaki A, Hanafusa T, Yamada K, Miyagawa J, Fujinokurihara H, Nakajima H, Nonaka K, Tarui S. Predominance of lymphocytes-T in pancreatic-islets and spleen of pre-diabetic non-obese diabetic (NOD) mice a longitudinal-study. Clin Exp Immunol 1985;60(3):622-630. 2. Leiter EH, Prochazka M, Coleman DL. The nonobese diabetic (NOD) 15 mouse. Am J Pathol 1987;128(2):380-383. 3. Yeh TC, Zhang W, Ildstad ST, Ho C. Intracellular labeling of T-cells with superparamagnetic contrast agents. Magn Reson Med 1993;30(5):617-625. 4. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. Tat peptide-derivatized magnetic nanoparticles allow in vivo 20 tracking and recovery of progenitor cells. Nat Biotechnol 2000;18(4):410 414. 5. Hoehn M, Kustermann E, Blunk J, Wiedermann D, Trapp T, Wecker S, Focking M, Arnold H, Hescheler J, Fleischmann BK, Schwindt W, Buhrle C. Monitoring of implanted stem cell migration in vivo: A highly resolved in 25 vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA 2002;99(25):16267-16272. 6. Ahrens ET, Feili-Hariri M, Xu H, Genove G, Morel PA. Receptor-mediated endocytosis of iron-oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging. Magn Reson Med 2003;49(6):1006-1013. 30 7. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, Weissleder R. In vivo high resolution three-dimensional imaging of antigen- WO 2007/120911 PCT/US2007/009391 72 specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res 2003;63(20):6838-6846. 8. Bulte JWM, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Method 5 Enzymol 2004;386:275-299. 9. Modo M, Mellodew K, Cash D, Fraser SE, Meade TJ, Price J, Williams SCR. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage 2004;21(1):311-317. 10. Billotey C, Aspord C, Beuf 0, Piaggio E, Gazeau F, Janier MF, Thivolet C. 10 T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging. Radiology 2005;236(2):579-587. 11. Moore A, Grimm J, Han B, Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 2004;53(6):1459-1466. 15 12. Anderson SA, Shukaliak-Quandt J, Jordan EK, Arbab AS, Martin R, McFarland H, Frank JA. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 2004;55(5):654-659. 13. Evgenov NV, Medarova Z, Pratt J, Pantazopoulos P, Leyting S, Bonner Weir S, Moore A. In vivo imaging of immune rejection in transplanted 20 pancreatic islets. Diabetes 2006;55(9):2419-2428. 14. Evgenov NV, Medarova Z, Dai GP, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med 2006; 12(1):144-148. 15. Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, Mathis D. Noninvasive imaging of pancreatic inflammation and its reversal 25 in type 1 diabetes. J Clin Invest 2005; 115(9):2454-246 1. 16. Wu YL, Ye Q, Foley LM, Hitchens TK, Sato K, Williams JB, Ho C. In situ labeling of immune cells with iron oxide particles: An approach to detect organ rejection by cellular MRI. Proc Natl Acad Sci USA 2006; 103(6):1852 1857. 30 17. Shapiro EM, Sharer K, Skrtic S, Koretsky AP. In vivo detection of single cells by MRI. Magn Reson Med 2006;55(2):242-249.
WO 2007/120911 PCT/US2007/009391 73 18. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol 2005;23(8):983-987. 19. You S, Chen C, Lee WH, Wu CH, Judkowski V, Pinilla C, Wilson DB, Liu CP. Detection and characterization of T cells specific for BDC2.5 T cell 5 stimulating peptides. J Immunol 2003;170(8):4011-4020. 20. Ablamunits V, Quintana F, Reshef T, Elias D, Cohen IR. Acceleration of autoimmune diabetes by cyclophosphamide is associated with an enhanced IFN-gamma secretion pathway. J Autoimmun 1999;13(4):383-392. 21. Gudbjartsson H, Patz S. The Rician distribution of noisy MRI data. Magn 10 Reson Med 1995;34(6):910-914. 22. Cantor J, Haskins K. Effector function of diabetogenic CD4 Thl T cell clones: a central role for TNF-alpha. J Immunol 2005;175(11):7738-7745. . 23. Phillips JM HS, Parish NM, Fehervari Z, Haskins K, Cooke A. Nondepleting anti-CD4 has an immediate action on diabetogenic effector cells, halting 15 their destruction of pancreatic beta cells. J Immunol 2000;165(4):1949-1955. 24. Meyer KL, Joseph PM, Mukherji B, Livolsi VA, Lin R. Measurement of vascular volume in experimental rat tumors by 19F magnetic resonance imaging. Invest Radiol 1993;28(8):710-719. 25. Fishman JE, Joseph PM, Floyd TF, Mukherji B, Sloviter HA. Oxygen 20 sensitive 19F NMR imaging of the vascular system in vivo. Magn Reson Imaging 1987;5(4):279-285. 26. Eidelberg D, Johnson G, Barnes D, Tofts PS, Delpy D, 'Plummer D, McDonald WI. 19F NMR imaging of blood oxygenation in the brain. Magn Reson Med 1988;6(3):344-352. 25 27. Wilson CA, Berkowitz BA, McCuen BW, Charles HC. Measurement of preretinal oxygen-tension in the vitrectomized human eye using F-1 9 magnetic resonance spectroscopy. Arch Ophthalmol-Chic 1992;110(8):1098 1100. 28. Dardzinski BJ, Sotak CH. Rapid tissue oxygen tension mapping using 19F 30 inversion-recovery echo- planar imaging of perfluoro-15-crown-5-ether. Magn Reson Med 1994;32(l):88-97.
WO 2007/120911 PCT/US2007/009391 74 29. Noth U, Morrissey SP, Deichmann R, Adolf H, Schwarzbauer C, Lutz J, Haase A. In vivo measurement of partial oxygen pressure in large vessels and in the reticuloendothelial system using fast 19F-MRI. Magn Reson Med 1995;34(5):738-745. 5 30. Lutz J, Noth U, Morrissey SP, Adolf H, Deichmann R, Haase A. Measurement of oxygen tensions in the abdominal cavity and in the skeletal muscle using 19F-MRI of neat PFC droplets. Adv Exp Med Biol 1997;428:569-572. 31. Duong TQ, Kim SG. In vivo MR measurements of regional arterial and 10 venous blood volume fractions in intact rat brain. Magn Reson Med 2000;43(3):393-402. 32. Xia MN, Kodibagkar V, Liu HL, Mason RP. Tumour oxygen dynamics measured simultaneously by near-infrared spectroscopy and F-19 magnetic resonance imaging in rats. Phys Med Biol 2006;51(1):45-60. 15 -33. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted F-19 nanoparticles. Magn Reson Med 2004;52(6):1255-1262. 34. Lanza GM, Winter PM, Neubauer AM, Caruthers SD, Hockett FD, Wickline 20 SA. IH/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. In: Ahrens ET, editor. In vivo cellular and molecular imaging. Volume 70. Current topics in developmental biology. San Diego: Elsevier; 2005. p 58-78. 35. Pelchen-Matthews A, Parsons IJ, Marsh M. Phorbol ester-induced 25 downregulation of CD4 is a multistep process involving dissociation from p561ck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 1993;178(4):1209-1222. 36. Phillips JM, Haskins K, Cooke A. MAdCAM-1 is needed for diabetes development mediated by the T cell clone, BDC-2.5. Immunology 30 2005; 116(4):525-531.
WO 2007/120911 PCT/US2007/009391 75 37. Pakala SV, Kurrer MO, Katz JD. T helper 2 (Th2) T cells induce acute pancreatitis and diabetes in immune-compromised nonobese diabetic (NOD) mice. J Exp Med 1997;186(2):299-306. 38. Fabien N, Bergerot I, Maguer-Satta V, Orgiazzi J, Thivolet C. Pancreatic 5 lymph nodes are early targets of T cells during adoptive transfer of diabetes in NOD mice. J Autoimmun 1995;8(3):323-334. 39. Miller MJ, Safrina 0, Parker I, Cahalan MD. Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. J Exp Med 2004;200(7):847-856. 10 40. Ribeiro RM, Mohri H, Ho DD, Perelson AS. In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted Proc Natl Acad Sci USA 2002;99(24):15572-15577. 41. Feili-Hariri, M., et al., Immunotherapy of NOD mice with bone marrow derived dendritic cells. Diabetes, 1999. 48: 2300-2308. 15 42. Pluchino, S., et al., Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature, 2003. 422(6933): p. 688-694. 43. Yeh, T.C., et al., In-vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med, 1995. 33: 200 208. 20 44. Schulze, E., et al., Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol, 1995. 30(10): 604-10. 45. Moore, A., R. Weissleder, and A. Bogdanov, Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. JMRI-Joumal of Magnetic Resonance Imaging, 1997. 7(6): 1140-1145. 25 46. Weissleder, R., et al., Magnetically labeled cells can be detected by MR imaging. JMRI-Journal of Magnetic Resonance Imaging, 1997. 7(1): 258 263. 47. Schoepf, U., et al., Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques, 1998. 24(4): 642-+. 30 48. Ye, Q., et al., In vivo detection of acute rat renal allograft rejection by MRI with USPIO particles. Kidney International, 2002. 61(3): 1124-1135. 49. Dousset, V., et al., In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magnetic Resonance in Medicine, 1999. 41(2): 329-333. 35 50. Josephson, L., et al., High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjugate Chemistry, 1999. 10(2): 186-191. 51. Dodd, C.H., et al., Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived 40 superparamagnetic nanoparticles. Journal of Immiunological Methods, 2001. 256(1-2): 89-105.
WO 2007/120911 PCT/US2007/009391 76 52. Kanno, S., et al., Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation, 2001. 104(8): 934-938. 53. McGoron, A.J., et al., Perfluorocarbon distribution to liver, lung and spleen 5 of emulsions of perfluorotributylamine (FTBA) in pigs and rats and perfluorooctyl bromide (PFOB) in rats and dogs by F-19 NMR spectroscopy. Artificial Cells Blood Substitutes and Immobilization Biotechnology, 1994. 22(4): 1243-1250. 54. Noth, U., et al., Perfluoro-1 5-crown-5-ether labelled macrophages in 10 adoptive transfer experimental allergic encephalomyelitis. Artificial Cells Blood Substitutes and Immobilization Biotechnology, 1997. 25(3): 243-254. 55. Girolomoni, G., et al., Establishment of a cell-line with features of early dendritic cell precursors from fetal mouse skin. European Journal of Immunology, 1995. 25(8): 2163-2169. 15 56. W02005072780 57. Arbab, A.S., et al., Blood, 2004. Aug 15;104(4):1217-23. 58. Floris S., et al., Brain. 2004 Mar;127(Pt 3):616-27. 59. US patent 5,958,371 60. US patent application 20020192688 20 EQUIVALENTS While specific embodiments of the subject inventions are explicitly disclosed herein, the above specification is illustrative and not restrictive. Many variations of the inventions will become apparent to those skilled in the art upon review of this 25 specification and the claims below. The full scope of the inventions should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

权利要求:
Claims (61)
[1] 2. The method of claim 1, wherein the fluorocarbon imaging reagent is a perfluoropolyether.
[2] 3. The method of claim 1, wherein the fluorocarbon imaging reagent is a perfluoro-crown ether.
[3] 4. The method of claim 1, wherein the imaging reagent is a perfluro-1 5-crown
[4] 5-ether. 5. The method of claim 1, wherein the fluorocarbon is a perfluorinated polyether having an average formula: XO(Y-O).Z wherein Y is selected from the group comprising: F F F F F C--- , C-C-- and F F F F F F F F F C----C-- I I I I F F F F WO 2007/120911 PCT/US2007/009391 78 wherein n is an integer from 8 to 20; wherein X and Z are the same and are selected from the group comprising: perfluoroalkyls, perfluoroethers, fluoroalkyls terminated with fluoroacyl, carboxyl, amide or ester, methylols, acid chlorides, amides, amidines, acrylates and esters.
[5] 6. The method of claim 1, wherein the fluorocarbon imaging reagent is selected from the group comprising: a linear perfluoropolyether, a cyclic perfluoropolyether and a mixture thereof
[6] 7. The method of claim 1, wherein prior to administration to the subject, the cells are contacted with a composition comprising the fluorocarbon imaging reagent, whereby the cells are labeled with the fluorocarbon imaging reagent.
[7] 8. The method of claim 1, wherein prior to administration to the subject, the cells are labeled with perfluorocarbon emulsion particles using electroporation.
[8] 9. The method of claim 7, wherein the composition comprising the fluorocarbon imaging reagent further comprises an uptake enhancing reagent.
[9] 10. The method of claim 7, wherein the composition comprising the fluorocarbon imaging reagent further comprises: a. a surfactant; and b. a cationic lipid.
[10] 11. The method of claim 9, wherein the uptake enhancing reagent comprises a compound selected from the group consisting of: a. cationic lipid; and b. cationic polypeptide.
[11] 12. The method of claim 11, wherein the cationic peptide is a protamine.
[12] 13. The method of claim 7, wherein at least a portion of the fluorocarbon imaging reagent is internalized into the cell. WO 2007/120911 PCT/US2007/009391 79
[13] 14. The method of claim 7, wherein the composition comprising the fluorocarbon imaging reagent further comprises Pluronic L-35.
[14] 15. The method of claim 7, wherein the fluorocarbon imaging reagent is formulated as an emulsion.
[15] 16. The method of claim 7, wherein the emulsion comprises particles having a mean diameter of between 30 and 500 nm.
[16] 17. The method of claim 1, wherein the cell is a mammalian cell.
[17] 18. The method of claim 1, wherein the cell is a cell of the immune system.
[18] 19. The method of claim 1, wherein the cell is a T cell.
[19] 20. The method of claim 1, wherein the cell is a dendritic cell.
[20] 21. The method of claim 1, wherein the cell is a stem cell.
[21] 22. The method of claim 1, wherein examining by a nuclear magnetic resonance technique comprises collecting a ' 9 F data set.
[22] 23. The method of claim 1, further comprising collecting a 'H data set.
[23] 24. The method of claim 1, further comprising generating and comparing a '9F image and a 'H image.
[24] 25. The method of claim 1, wherein the nuclear magnetic resonance technique is magnetic resonance imaging (MRI).
[25] 26. The method of claim 1, wherein the nuclear magnetic resonance technique is magnetic resonance spectroscopy (MRS).
[26] 27. The method of claim 1, wherein the cell is administered to the subject as part of a cellular therapeutic regimen.
[27] 28. A method for quantifying the number of cells labeled with a fluorocarbon imaging reagent in a recipient of a transplant that includes said labeled cells, the method comprising: a. examining at least a portion of the subject by a nuclear magnetic resonance technique, thereby detecting labeled cells in the subject. WO 2007/120911 PCT/US2007/009391 80 b. quantifying the number of labeled cells.
[28] 29. The method of claim 28, wherein the location and optionally the trafficking of labeled cells is detected in the transplant recipient.
[29] 30. The method of claim 28, wherein the nuclear magnetic resonance technique is selected from the group comprising: magnetic resonance imaging and magnetic resonance spectroscopy.
[30] 31. The method of claim 28, wherein the transplant recipient is a bone marrow transplant recipient.
[31] 32. The method of claim 28, wherein the cells for transplant comprise hematopoietic stem cells.
[32] 33. The method of claim 28, wherein the cells for transplant are derived from bone marrow, cord blood or peripheral blood.
[33] 34. The method of 'claim 28, wherein the transplant recipient is the recipient of a donor organ.
[34] 35. The method of claim 28, wherein at least a portion of the cells of the donor organ are labeled with a fluorocarbon imaging reagent.
[35] 36. The method of claim 28, wherein the transplant recipient is a human.
[36] 37. The method of claim 1, wherein quantifying comprises using a calibrated ' 9 F signal in the ROL
[37] 38. The method of claim 28, wherein quantifying comprises using a calibrated 19F signal in the RO.
[38] 39. The method of claim 1 or 28, wherein examining comprises detecting a pre calibrated 1 9 F signal from which one can deduce a relationship between the 1F signal in 'the ROI and the representative number of 1 9 F molecules or cell quantity.
[39] 40. The method of claim I or 28, wherein examining comprises detecting a contemporaneous signal in the ROI from which one can deduce a WO 2007/120911 PCT/US2007/009391 81 relationship between the signal and the representative number of 1 9 F molecules or cell quantity.
[40] 41. The method of claim I or 28, wherein examining comprises detecting a post calibrated 1 9 F signal in the ROI from which one can deduce a relationship between the signal and the representative number of '9F molecules or cell quantity.
[41] 42. The method of claim 37, wherein the cellular dose of fluorocarbon imaging reagent is calculated prior to administration of cells to the subject.
[42] 43. The method of claim 38, wherein the cellular dose of fluorocarbon imaging reagent is calculated prior to transplantation.
[43] 44. The method of claim 1, wherein quantifying is done by comparison to a calibrated external 1 9 F reference during the 1 9 F MRI/MRS scan of the subject.
[44] 45. The method of claim 28, wherein quantifying is done by comparison to a calibrated external 1 9 F reference during the 1 9 F MRI/MRS scan of the subject.
[45] 46. The method of claim 44, wherein the reference is a cell free reference.
[46] 47. The method of claim 45, wherein the reference is a cell free reference.
[47] 48. The method of claim 1, wherein quantifying comprises calculating ratios of the intensity of 1 9 F signal and the volume of labeled cells in a ROI compared to a reference.
[48] 49. The method of claim 28, wherein quantifying comprises calculating ratios of the intensity of ' 9 F signal and the volume of labeled cells in a ROI compared to a reference.
[49] 50. The method of claim 1, wherein quantifying the number of labeled cells comprises using at least one of the parameters from the group consisting of: (i) the cellular dose of.labeling agent (i.e., F.) measured in vitro; (ii) in vivo '9F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane WO 2007/120911 PCT/US2007/009391 82 voxel area (i.e., area of the image pixel); (v) the MRI/MRS data set from the 1 9 F reference standard; (vi) the measured Johnson noise of the "F MRI/MRS data in the subject material; (vii) the measured signal-to-noise ratio (SNR) of one or more voxels of the 1 9 F MRI/MRS data set in the subject material; (viii) the measured SNR of one or more voxels of the 19F MRI/MRS data set from the reference standard; (ix) the ' 9 F NMR relaxation times (TI, T2, and T2*) of the subject material; and (x) the 1 9 F NMR relaxation times (TI, T2, and T2*) of the reference standard.
[50] 51. The method of claim 1, wherein quantifying the number of labeled cells comprises using the formula: N _ [,]v 1 O " IR F where: Nc = total number of labeled cells in the ROI; [FR) = concentration of 19F in the calibrated ' 9 F reference solution (or gel); v = voxel volume; IR = mean intensity of the calibrated 1 9 F reference taken with the MRI/MRS scan, averaged over one or more voxels; Fe = average 1 9 F cellular dose of the labeling agent measured in vitro; NROI = number of voxels in the ROI containing labeled cells; Ic 1 = image intensity of the ith voxel in the ROI containing labeled cells; i = unitless index for voxels in the ROI containing labeled cells.
[51] 52. The method of claim 28, wherein quantifying the number of labeled cells comprises using at least one of the parameters from the group consisting of: (i) the cellular dose of labeling agent (i.e., F,) measured in vitro; (ii) in vivo 19F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane voxel area (i.e., area of the image pixel); (v) the MRI/MRS data set from the 1 9 F reference standard; (vi) the measured Johnson noise of the ' 9 F MRI/MRS data in the subject material; (vii) the measured signal-to-noise ratio (SNR) of one or more voxels of the 1 9 F MRI/MRS data set in the subject material; (viii) the measured SNR of one or more voxels of the ' 9 F WO 2007/120911 PCT/US2007/009391 83 MRI/MRS data set from the reference standard; (ix) the ' 9 F NMR relaxation times (T1, T2, and T2*) of the subject material; and (x) the ' 9 F NMR relaxation times (TI, T2, and T2*) of the reference standard.
[52] 53. The method of claim 28, wherein quantifying the number of labeled cells comprises using the formula: N =[FR ]v 1 IR FL !i l
[53] 54. A calculating system for the quantification of ' 9 F labeled cells, the system comprising: a computer; a computer readable medium, operatively coupled to the computer, the computer readable medium programs codes performing functions comprising: quantification of 19F labeled cells in a ROI examined by a magnetic resonance technique.
[54] 55. The system according to claim 54, wherein quantification comprises relating a calibrated NMR signal to a cellular dose or cell quantity.
[55] 56. The system according to claim 54, wherein the functions are comprising: calculating the number of labeled cells by ratios of the intensity of ' 9 F signal and the volume of labeled cells in a ROI compared to a reference.
[56] 57. The system according to claim 54, wherein the functions are comprising: calculating the number of labeled cells using at least one of the parameters from the group consisting of: (i) the cellular dose of labeling agent (i.e., F,) measured in vitro; (ii) in vivo 19F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane voxel area (i.e., area of the image pixel); (v) the MRI/MRS data set from the WO 2007/120911 PCT/US2007/009391 84 1 9 F reference standard; (vi) the measured Johnson noise of the 19F MRI/MRS data in the subject material; (vii) the measured signal-to-noise ratio (SNR) of one or more voxels of the ' 9 F MRI/MRS data set in the subject material; (viii) the measured SNR of one or more voxels of the 1 9 F MRI/MRS data set from the reference standard; (ix) the 1 9 F NMR relaxation times (TI, T2, and T2*) of the subject material; and (x) the 19 F NMR relaxation times (TI, T2, and T2*) of the reference standard.
[57] 58. The system according to claim 54, wherein the functions are comprising: calculating the number of labeled cells according to the formula: [FR ]v F Iv * IR F7 =
[58] 59. A computer readable medium having computer readable program codes embodied therein for performing in vivo quantification of 1 9 F labeled cells, the computer readable medium program codes performing functions comprising: calculating the number of ' 9 F labeled cells in a ROI detected by a magnetic resonance technique.
[59] 60. The system according to claim 59, wherein the functions are comprising: calculating the number of labeled cells by ratios of the intensity of 1 9 F signal and the volume of labeled cells in a ROI compared to a reference.
[60] 61. The system according to claim 59, wherein the functions are comprising: calculating the number of labeled cells using at least one of the parameters from the group consisting of: (i) the cellular dose of labeling agent (i.e., Fc) measured in vitro; (ii) in vivo 1 9 F MRI/MRS data set taken in the subject at one or more time points following labeled cell administration; (iii) the voxel volume; (iv) the in-plane voxel area (i.e., area of the image pixel); (v) the MRI/MRS data set from the 1F reference standard; (vi) the measured Johnson noise of the '9F MRI/MRS WO 2007/120911 PCT/US2007/009391 85 data in the subject material; (vii) the measured signal-to-noise ratio (SNR) of one or more voxels of the 1 9 F MRI/MRS data set in the subject material; (viii) the measured SNR of one or more voxels of the 19F MRI/MRS data set from the reference standard; (ix) the ' 9 F NMR relaxation times (TI, T2, and T2*) of the subject material; and (x) the ' 9 F NMR relaxation times (TI, T2, and T2*) of the reference standard.
[61] 62. The system according to claim 59, wherein the functions are comprising: calculating the number of labeled cells according to the formula: N - [FR]v I " IR F:

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2007238586B2|2014-03-20|Cellular labeling and quantification for nuclear magnetic resonance techniques

---

US8449866B2|2013-05-28|Cellular labeling for nuclear magnetic resonance techniques

---

EP2170975B1|2018-05-02|Compositions and methods for producing cellular labels for nuclear magnetic resonance techniques

---

US9352057B2|2016-05-31|Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications

---

US20070258886A1|2007-11-08|Methods for assessing cell labeling

同族专利:

---

公开号 | 公开日

---

CA2649333C|2016-10-04|

---

EP2010646A2|2009-01-07|

---

US20070253910A1|2007-11-01|

---

WO2007120911A2|2007-10-25|

---

JP2009533684A|2009-09-17|

---

US8263043B2|2012-09-11|

---

CA2649333A1|2007-10-25|

---

WO2007120911A3|2008-10-16|

---

AU2007238586B2|2014-03-20|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US4094911A|1969-03-10|1978-06-13|Minnesota Mining And Manufacturing Company|Poly derivatives|

---

US4558279A|1983-03-07|1985-12-10|University Of Cincinnati|Methods for detecting and imaging a temperature of an object by nuclear magnetic resonance|

---

US4714680B1|1984-02-06|1995-06-27|Univ Johns Hopkins|Human stem cells|

---

US4570004A|1984-04-06|1986-02-11|The Board Of Regents, University Of Texas System|Perfluoro crown ethers|

---

US4987154A|1986-01-14|1991-01-22|Alliance Pharmaceutical Corp.|Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use|

---

IL82308A|1986-06-26|1990-11-29|Ausimont Spa|Microemulsions containing perfluoropolyethers|

---

US4783401A|1986-10-31|1988-11-08|Smithkline Beckman Corporation|Viable cell labelling|

---

US4838274A|1987-09-18|1989-06-13|Air Products And Chemicals, Inc.|Perfluoro-crown ethers in fluorine magnetic resonance imaging|

---

US4935223A|1988-08-04|1990-06-19|Board Of Regents, The University Of Texas System|Labeled cells for use in imaging|

---

US4996041A|1988-08-19|1991-02-26|Toshiyuki Arai|Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system|

---

US5539059A|1988-09-28|1996-07-23|Exfluor Research Corporation|Perfluorinated polyethers|

---

US4881032A|1988-10-21|1989-11-14|General Electric Company|Method of, and apparatus for, NMR spectroscopic metabolite imaging and quantification|

---

IT1229222B|1989-03-31|1991-07-26|Ausimont Srl|STABLE EMULSIONS OF PERFLUOROPOLYETERS|

---

US5114703A|1989-05-30|1992-05-19|Alliance Pharmaceutical Corp.|Percutaneous lymphography using particulate fluorocarbon emulsions|

---

US5437994A|1989-06-15|1995-08-01|Regents Of The University Of Michigan|Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 secretion of human stromal cells|

---

US5236694A|1990-02-21|1993-08-17|The Board Of Regents, The University Of Texas System|19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents|

---

GB9006522D0|1990-03-23|1990-05-23|Hider Robert C|Metal complexes|

---

US5061620A|1990-03-30|1991-10-29|Systemix, Inc.|Human hematopoietic stem cell|

---

US5196348A|1990-06-11|1993-03-23|Air Products And Chemicals, Inc.|Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue|

---

US5486359A|1990-11-16|1996-01-23|Osiris Therapeutics, Inc.|Human mesenchymal stem cells|

---

US5851832A|1991-07-08|1998-12-22|Neurospheres, Ltd.|In vitro growth and proliferation of multipotent neural stem cells and their progeny|

---

US5403575A|1991-12-12|1995-04-04|Hemagen/Pfc|Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them|

---

DE4203254C2|1992-02-05|1996-05-02|Max Planck Gesellschaft|Fluorine-containing marker compound for NMR investigations and their use|

---

WO1994000484A1|1992-06-22|1994-01-06|Young Henry E|Scar inhibitory factor and use thereof|

---

JPH08500245A|1992-07-27|1996-01-16|カリフォルニアインスティテュートオブテクノロジー|Mammalian pluripotent neural stem cells|

---

US5589376A|1992-07-27|1996-12-31|California Institute Of Technology|Mammalian neural crest stem cells|

---

US5766948A|1993-01-06|1998-06-16|The Regents Of The University Of California|Method for production of neuroblasts|

---

DE69433723T3|1993-02-22|2008-10-30|Abraxis Bioscience, Inc., Los Angeles|PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM|

---

WO1994021303A1|1993-03-16|1994-09-29|Alliance Pharmaceutical Corp.|Fluorocarbon compositions containing a visible or fluorescent label|

---

US5972703A|1994-08-12|1999-10-26|The Regents Of The University Of Michigan|Bone precursor cells: compositions and methods|

---

AT345682T|1996-05-01|2006-12-15|Imarx Pharmaceutical Corp|IN VITRO PROCESS FOR INTRODUCING NUCLEIC ACIDS INTO A CELL|

---

US5843780A|1995-01-20|1998-12-01|Wisconsin Alumni Research Foundation|Primate embryonic stem cells|

---

US5736396A|1995-01-24|1998-04-07|Case Western Reserve University|Lineage-directed induction of human mesenchymal stem cell differentiation|

---

US5925567A|1995-05-19|1999-07-20|T. Breeders, Inc.|Selective expansion of target cell populations|

---

US5958371A|1995-06-08|1999-09-28|Barnes-Jewish Hospital|Site specific binding system, nuclear imaging compositions and methods|

---

US5690907A|1995-06-08|1997-11-25|The Jewish Hospital Of St. Louis|Avidin-biotin conjugated emulsions as a site specific binding system|

---

US5780010A|1995-06-08|1998-07-14|Barnes-Jewish Hospital|Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system|

---

US6190910B1|1996-05-21|2001-02-20|The Institute Of Physical And Chemical Research|Mouse embryonic stem cell lines|

---

US5753506A|1996-05-23|1998-05-19|Cns Stem Cell Technology, Inc.|Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals|

---

US20020016002A1|2000-01-24|2002-02-07|Jean Toma|Multipotent neural stem cells from peripheral tissues and uses thereof|

---

US7544509B2|2000-01-24|2009-06-09|Mcgill University|Method for preparing stem cell preparations|

---

US20020123143A1|1997-08-22|2002-09-05|Jean Toma|Multipotent stem cells from peripheral tissues and uses thereof|

---

US6063593A|1996-11-12|2000-05-16|University Of Southern California University Park Campus|TGFβ1 responsive bone marrow derived cells to express a recombinant protein|

---

US6331406B1|1997-03-31|2001-12-18|The John Hopkins University School Of Medicine|Human enbryonic germ cell and methods of use|

---

US6090622A|1997-03-31|2000-07-18|The Johns Hopkins School Of Medicine|Human embryonic pluripotent germ cells|

---

US6361996B1|1997-05-07|2002-03-26|University Of Utah Research Foundation|Neuroepithelial stem cells and glial-restricted intermediate precursors|

---

US7514074B2|1997-07-14|2009-04-07|Osiris Therapeutics, Inc.|Cardiac muscle regeneration using mesenchymal stem cells|

---

US6171610B1|1998-04-24|2001-01-09|University Of Massachusetts|Guided development and support of hydrogel-cell compositions|

---

DE19830697C2|1998-07-08|2001-06-07|Metallgesellschaft Ag|Process for removing relatively coarse-grained solids from a stationary fluidized bed|

---

US6468794B1|1999-02-12|2002-10-22|Stemcells, Inc.|Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations|

---

KR100968164B1|1999-03-10|2010-07-06|더 리전츠 오브 더 유니버시티 오브 캘리포니아|Adipose-derived stem cells and lattices|

---

US6511967B1|1999-04-23|2003-01-28|The General Hospital Corporation|Use of an internalizing transferrin receptor to image transgene expression|

---

CA2403000C|2000-03-14|2015-06-23|Es Cell International Pte Ltd|Embryonic stem cells and neural progenitor cells derived therefrom|

---

US6921632B2|2000-08-30|2005-07-26|Maria Biotech Co., Ltd.|Human embryonic stem cells derived from frozen-thawed embryo|

---

US20020192688A1|2001-04-05|2002-12-19|Xiaoming Yang|Imaging nucleic acid delivery|

---

US20050244384A1|2002-04-01|2005-11-03|Law Peter K|Cellular transplantation for heart regeneration|

---

US7357937B2|2002-09-24|2008-04-15|Therox, Inc.|Perfluorocarbon emulsions with non-fluorinated surfactants|

---

US20040109824A1|2002-12-06|2004-06-10|Hinds Kathleen Allison|Particles for imaging cells|

---

WO2004096998A2|2003-04-29|2004-11-11|Vanderbilt University|Nanoparticular tumor targeting and therapy|

---

CA2534426A1|2003-08-08|2005-02-17|Barnes-Jewish Hospital|Emulsion particles for imaging and therapy and methods of use thereof|

---

US8147806B2|2004-01-16|2012-04-03|Carnegie Mellon University|Cellular labeling for nuclear magnetic resonance techniques|

---

US20060040389A1|2004-08-17|2006-02-23|Murry Charles E|Purified compositions of stem cell derived differentiating cells|

---

US20060239919A1|2005-03-04|2006-10-26|Wickline Samuel A|MR coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 T|

---

JP4498218B2|2005-06-03|2010-07-07|信越化学工業株式会社|Fluorine-containing amide compound and process for producing the same|

---

WO2007100715A2|2006-02-24|2007-09-07|Washington University|Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy|

---

US8263043B2|2006-04-14|2012-09-11|Carnegie Mellon University|Cellular labeling and quantification for nuclear magnetic resonance techniques|

---

JP2009533061A|2006-04-14|2009-09-17|セルセンス，インコーポレイテッド|Methods for assessing cell labeling|

---

DE102007015598A1|2007-03-29|2008-10-02|Heinrich-Heine-Universität Düsseldorf|Use of fluorochemical compounds for diagnostic purposes using imaging techniques|

---

WO2008144028A1|2007-05-14|2008-11-27|The Johns Hopkins University|Methods for in vivo imaging of cells|

---

JP5645658B2|2007-07-10|2014-12-24|カーネギー メロン ユニバーシティー|Compositions and methods for producing cell labels for nuclear magnetic resonance technology|US8147806B2|2004-01-16|2012-04-03|Carnegie Mellon University|Cellular labeling for nuclear magnetic resonance techniques|

---

WO2007100715A2|2006-02-24|2007-09-07|Washington University|Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy|

---

JP2009533061A|2006-04-14|2009-09-17|セルセンス，インコーポレイテッド|Methods for assessing cell labeling|

---

US8263043B2|2006-04-14|2012-09-11|Carnegie Mellon University|Cellular labeling and quantification for nuclear magnetic resonance techniques|

---

US8526689B2|2007-02-14|2013-09-03|Pola Chemical Industries Inc|Method of supporting the differentiation of corneocytes|

---

US20100201361A1|2007-05-03|2010-08-12|Edelman Robert R|System and method for passive catheter tracking with magnetic resonance imaging|

---

US20080272776A1|2007-05-03|2008-11-06|Edelman Robert R|Magnetic resonance image acquisition with suppression of background tissues and rf water excitation at offset frequency|

---

JP5645658B2|2007-07-10|2014-12-24|カーネギー メロン ユニバーシティー|Compositions and methods for producing cell labels for nuclear magnetic resonance technology|

---

KR100957560B1|2007-10-18|2010-05-11|한국생명공학연구원|Perfluorocarbon Nano Emulsion Containing Quantum Dot Nanoparticles and Method for Preparing Thereof|

---

US7692424B2|2008-02-28|2010-04-06|Magnetic Resonance Innovations, Inc.|Method of and software application for quantifying objects in magnetic resonance images via multiple complex summations|

---

KR101031049B1|2008-04-17|2011-04-25|한국생명공학연구원|Labeling and Imaging of Cells using Multifunctional Perfluorocarbon nano Emulsions|

---

ES2611103T3|2008-05-02|2017-05-04|Celsense Inc.|Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications|

---

KR101005561B1|2008-06-21|2011-01-05|한국생명공학연구원|The multimodal imaging method using nano-emulsion consisted of optical nano-particles and perfluorocarbons|

---

FR2934050B1|2008-07-15|2016-01-29|Univ Paris Curie|METHOD AND DEVICE FOR READING EMULSION|

---

US8761860B2|2009-10-14|2014-06-24|Nocimed, Llc|MR spectroscopy system and method for diagnosing painful and non-painfulintervertebral discs|

---

US8825131B2|2009-10-14|2014-09-02|Nocimed, Llc|MR spectroscopy system and method for diagnosing painful and non-painful intervertebral discs|

---

US9280718B2|2010-11-24|2016-03-08|Nocimed, Llc|Systems and methods for automated voxelation of regions of interest for magnetic resonance spectroscopy|

---

EP2740073B1|2011-06-17|2017-01-18|Quantitative Imaging, Inc.|Methods and apparatus for assessing activity of an organ and uses thereof|

---

US9034589B2|2012-03-22|2015-05-19|Board Of Regents, The University Of Texas System|Magnetic separation of cells|

---

US8965094B2|2012-04-14|2015-02-24|Nocimed, Llc|Magnetic resonance spectroscopy pulse sequence, acquisition, and processing system and method|

---

WO2013158265A1|2012-04-20|2013-10-24|Genelux Corporation|Imaging methods for oncolytic virus therapy|

---

DE102012218913B4|2012-10-17|2015-12-31|Siemens Aktiengesellschaft|Method for determining at least one date of an implanted silicone implant and magnetic resonance apparatus therefor|

---

WO2014172265A1|2013-04-19|2014-10-23|Sunnybrook Health Sciences Center|Focused ultrasound system for small bore imaging|

---

EP3139833A4|2014-05-09|2018-01-17|The Regents of the University of California|Cardiac phase-resolved non-breath-hold 3-dimensional magnetic resonance angiography|

---

EP3203256A1|2016-02-02|2017-08-09|B. Braun Melsungen AG|Calibration of mri systems using pre-defined concentrations of 19f isotopes as reference|

法律状态:
2014-07-17| FGA| Letters patent sealed or granted (standard patent)|

---

2019-11-14| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

US79200306P| true| 2006-04-14|2006-04-14||

---

US60/792,003||2006-04-14||

---

PCT/US2007/009391|WO2007120911A2|2006-04-14|2007-04-16|Cellular labeling and quantification for nuclear magnetic resonance techniques|

---